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Existing crystallographic methods require micro-meter sized crystals for structure 
determination.  However, due to their intrinsic disorder, many biological molecules are not 
amenable to the formation of such large crystals.  X-ray free electron lasers (X-FEL) provide a 
new avenue to determine crystal structures of such challenging biological targets, as this 
technology enables the acquisition of diffraction patterns from nano-meter sized crystals.  As 
proof of principle, X-FELs have been employed to determine crystal structures obtained using 
conventional crystallographic methods. A major limitation to the application of X-FEL 
technology to de novo structure determination of challenging targets is the inability to identify 
protein nanocrystals (NCs) that are suitable for diffraction by X-FEL.  Here, I establish a method 
using Transmission Electron Microscopy (TEM) to reliably identify and characterize protein 
NCs.  I then use this method to compare crystallographic seeding techniques to identify 
conditions that yield larger and higher quality NCs. 
Negative stain Transmission Electron Microscopy (TEM) was used to detect NCs of 
several challenging targets. One such challenging target is a Family B G-Protein Coupled 
Receptor, the parathyroid hormone receptor (PTHR1). Crystallization trials of the PTHR1 were 
performed to isolate potential NC containing drops. UV tryptophan fluorescence microscopy was 
employed to identify UV positive granular aggregates. Positive samples were examined by 
negative stain TEM with the aim of distinguishing NCs from protein aggregates. In those PTHR1 
NCs that were identified, the presence of negative stained lattices was used as an indicator of 
their proteic nature. This method was successfully employed to identify protein NCs of seven 
additional challenging targets. Crystal quality was determined by calculating fast Fourier 
transforms of NC lattices.   
 v 
TEM was also used to visualize crystallographic seeds for the first time, and identify 
optimal seeding conditions.   The quality of seeds produced by traditional seeding methods were 
compared to those produced by “nanoseeding,” a novel method in which multiple millimeter 
seed beads are used. The nanoseeding approach proved to be far superior to traditional methods 
at producing larger and higher quality seeds. This work demonstrates that TEM identified NCs, 
as well as fragmented NCs are powerful tools for optimizing and growing crystals. 
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1.0  INTRODUCTION 
Structural biologists who wish to determine and analyze structures of large proteins rely 
on the well-established techniques of X-ray crystallography. However, obtaining crystals of any 
protein is not always feasible, particularly when challenging targets are being pursued.  As a 
result, specific techniques for crystallizing targets such as membrane proteins have become more 
robust in the last 15 years in order to overcome crystallization challenges.  One example of this 
capitalizes on the instability of membrane receptors after extraction with detergent, and uses 
specific detergent concentrations to crystallize membrane receptors. However, in many 
instances, particularly with the G-Protein Coupled Receptors, the best efforts of structural 
biologists have failed to yield visible crystals. And in some cases, even after exhaustive 
optimization efforts, only small unusable crystals are obtained. Rather than focus on growing 
large crystals, as many have done in that past, this work seeks to use G-Protein Coupled 
Receptors as a model system to uncover novel methods for identifying and optimizing crystals 
for difficult targets for which no visible or usable crystals have previously been observed. 
1.1 G -PROTEIN COUPLED RECEPTORS 
G-protein coupled receptors (GPCRs) represent over 40% of drug targets in clinical use 
(1, 2). More than a thousand GPCRs have been identified to date, and they have immensely 
varying roles in human physiology (3, 4) including controlling cardiovascular homeostasis and 
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pathology (5), immune response (6, 7), and neurobiology that contributes to psychiatric 
conditions (8, 9), olfaction (10), taste (11) and vision (12, 13). Though these receptors play 
diverse roles in many different disease pathways, GPCRs share a common motif: seven 
transmembrane α-helices which are connected by alternating extracellular and intracellular loops. 
These extracellular and intracellular loops are the major sites of interactions for ligands and 
heterotrimeric G-proteins, respectively. 
1.1.1 GPCR Structure and Classification 
All GPCRs share the same basic structural features: a seven transmembrane α-helical 
structure that is connected by alternating loops. However, there are significant structural 
differences amongst GPCRs that can be used to categorized them into three distinct families, as 
well as several smaller seven-transmembrane families (14). All of these families share significant 
sequence homology amongst group members, but have as low as 2% sequence homology with 
GPCRs of other classes (3, 14, 15). Although these differences amongst the families of GPCRs 
are complex, an underlying distinction lies in the extracellular domains of these receptors as 
illustrated in Figure 1. This figure compares representative full-length crystal structures from the 
A and B Families as well as a full-length model of a Family C, of which only the extracellular 
domain has been solved. As this figure illustrates, the most noticeable difference between the 
structures is the distinct variation between their extracellular domains. It should be noted that to 
"solve" a structure, in the cases described in this text, refers to determining the relative 
coordinates of non-hydrogen atoms to sub-angstrom accuracy, such that specific residues are 
identifiable, reliable interatomic interaction distances can be measured, and atomic surface 
details revealed. 
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The Family A or Rhodopsin Family is the largest and most diverse of the GPCR families, 
comprised of several hundred members (3). Receptors from this family bind a variety of small 
molecule agonists such as small molecule ligands, neuropeptides and glycoproteins (16-19). 
These receptors commonly have a small extracellular domain (with the exception of glycoprotein 
hormone receptors) compared to other GPCR families (20). Binding sites for these ligands lies 
deep within the core of the receptor, interacting with TM3, 4, 5, 6 and 7 (16-19, 21). All but two 
of the 21 unique structures solved to date are of Family A receptors. 
The Secretin or Family B GPCRs are composed of 15 different members and regulate 
important physiological functions such as controlling exocrine and endocrine functions (14, 15, 
22-24). Unlike the Family A receptors, which includes a large variety of agonist types, the 
Family B GPCR bind extensively to endogenous polypeptide hormones approximately 30-40 
amino acids in length (25).  Such peptide hormones include secretin, vasoactive intestinal 
peptide, gastric inhibitory polypeptide, parathyroid hormone, and calcitonin (25). These 
receptors have common N-terminal ecto-domains approximately 120 amino acids in length, 
illustrated in the top portion of the Secretin Family GPCR example in Figure 1. Family B 
GPCRs and their ligands are thought to interact by a  “two domain” model (26, 27). In this 
model, the C-terminal of the ligand first binds to the receptor’s N-terminal ecto-domain. The 
ecto-domain of the receptor then orients the N-terminus of the polypeptide to the appropriate 
position for interacting with the extracellular loops and transmembrane helices of the GPCR 
(28).  
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Figure 1. Crystallographically determined structures of the three main classes GPCR. 
The Family C GPCRs, also known as the metabotropic glutamate receptor family, have a 
significantly larger extracellular domain then the other GPCR families, 500-600 amino acids in 
length (29, 30). The endogenous agonists of these receptors include sugar molecules, amino 
acids and ions (31, 32). No full-length structures of these receptors have been solved. Crystal 
structures of the extracellular domains of these receptors are reminiscent of a clamshell, with two 
lobes (33-35). This conformation oscillates between open and closed conformations with 
agonists being thought to bind in-between the cleft formed by the lobes (33-35). Another notable 
feature of these receptors is that they exist in a constitutively dimeric conformation within the 
cellular membrane, as both hetero and homo dimers (36-38).  
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1.1.2 GPCR Activation Cycle 
Figure 2. GPCR signaling. 
In the classical GPCR model, the binding of an extracellular agonist to the receptor 
triggers an intracellular conformational change that leads to the binding and activation of 
heterotrimeric G proteins (HGP) as shown in Figure 2. Activation of the HGP is made possible 
by a ligand-activated GPCR acting as a guanine nucleotide exchange factor (GEF). In this role 
the GPCR acts to facilitate the exchange from GDP to GTP of the α-subunit of the HGP. The 
HGP separates into a GTP-bound α-subunit and βγ subunits. These separated subunits are free to 
participate in downstream signaling until GTP hydrolysis occurs. The inactive GDP bound α-
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subunit then reassembles with its βγ counterparts and will remain inactive until the GPCR 
activates the HGP again. Activated HGP serves as the relays for the GPCR, linking the activation 
of the receptor to downstream cellular signaling. However, though GPCR GEF activity is 
stimulated by ligand binding, constitutive, low level GEF activity, is also a prevalent feature of 
these receptors (39-41). There are many Gα subunits, all of which contribute to different 
downstream signaling pathways (42, 43). The Gα subunit used for crystallographic examination 
of the interaction between GPCR and its HGP is GαS, as it binds most of the GPCRs crystallized 
to date (44, 45). GαS plays many roles in downstream signaling events once activated by its 
GPCR. One major role is to activate adenylate cyclase, thus acting as a relay for the GPCR in the 
AMP-dependent pathway (46). The biological consequences of activation of this pathway can 
include: increase heart rate, stimulation of neuronal activity and induction of smooth muscle 
relaxation (46-48). 
The common signaling behavior of all GPCRs across several structurally diverse families 
leads to questions of how such little sequence homology can result in universal signaling 
behavior.   Obtaining high-resolution structures of multiple activation states of Family A GPCRs 
has shed light on the basic structure and function of the largest of the GPCR classes. However, in 
obtaining crystal structures of different activation states of the β2AR for example, it became 
evident that the constitutive activity of GPCRs stems from the inherent flexibility of the receptor, 
the same flexibility that requires stabilization in order to achieve crystallization. These insights 
will likely be essential for the continued capture of the function and structure of other GPCR 
families by X-ray crystallography. 
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1.1.3 Strategies for the Crystallization of GPCRs 
Crystallizing and solving high-resolution structures of GPCRs has been a long standing 
crystallographic challenge. As further elaborated upon in section 1.2, highly ordered crystals are 
essential to X-ray crystallography as they are the backbone for solving structures of large 
proteins such as GPCRs. The challenge in obtaining these crystals is made evident by the long 
gap between the first GPCR structure solved in 2000, Rhodopsin, and the second, active form of 
the receptor Opsin, solved in 2008 (49-51). Many hurdles are associated with the crystallization 
of these proteins. The first is obtaining a functional receptor, which is particularly challenging 
because these receptors are naturally stabilized by lipids, requiring specific detergents to extract 
and stabilize these receptors. Additionally, these large, seven transmembrane receptors have 
crystallization-averse flexible regions. As such, these receptors’ disordered regions must be 
stabilized. The constitutive basal activity of GPCRs, a phenomenon consistently observed in the 
Family A receptors, also proves to be a crystallization challenge. 
1.1.3.1 Protein Manipulation Strategies for Crystallizing GPCRs 
Beyond obtaining an expression and purification protocol that produces adequate 
quantities of folded, functional protein, specific approaches to overcome the challenges 
associated with crystallizing these proteins have become essential. The primary barrier to 
crystallization of the receptor is a result of the inherent flexible domains of the protein. In order 
to overcome this challenge, crystallographers have focused on removing disordered regions of 
the protein that would interfere with crystallization. As shown in Figure 3, there are three main 
areas of predicted disorder that are evident in the Family A GPCRs structures that have already 
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been solved. The first two, the N and C terminus, always require truncation in order to grow 
diffractable crystals.  The third, and most challenging target for stabilization is the unstable 3rd 
intracellular loop (ICL3).  This region is, in a broadly simplistic view, the site of interaction of 
HGPs. Given the continuative activity of the receptor when not bound by ligand, stabilizing this 
region is required for crystallization (52).  
Figure 3. Predicted disorder for β2AR, generated by DISOPRED2 
One of the earliest approaches for stabilizing the ICL3, first successfully applied to the 
β2AR in its inactive conformation, was an antigen-binding fragment (Fab) designed against the 
ICL3. The Fab binding improved crystal contacts and stabilized the ICL3 as illustrated in Figure 
4A (52). The next successful technique applied to stabilize the ICL3, which is still widely used 
today, is to truncate the ICL3 and insert T4-lysozyme in its place. In addition to occupying the 
region previously filled by the ICL3, T4-lysozyme provides crystal contacts that enhance the 
likelihood of successful crystallization. This technique has been successfully utilized for 19 
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unique structures of Family A GPCRs (Figure 4B) (53-60). A third approach, illustrated in 
Figure 4C, was utilized to solve the inactive turkey β1AR receptor structure (61). Of the three 
techniques described here for inactive conformations of the receptor, only this approach left the 
ICL3 mostly intact. Instead of using a Fab or a GPCR-T4-lysozyme construct, the ICL3 was 
mutated and thermostabilized to reduce the intrinsic flexibility of the loop. The resulting 
mutations locked the ICL3 into an inactive, antagonist bound conformation, thereby inhibiting 
the agonist-independent constitutional activity of the protein (61). All GPCR structures solved to 
date rely on truncating the N and C terminal, removing glycosylation in extracellular loops of the 
receptor and stabilizing the ICL3 through use of a Fab, T4-lysozyme or thermostabilization of 
the ICL3. 
Figure 4. Successful Family A GPCR crystallization approaches. 
Point mutations, aimed at thermostabilizing Family A GPCRs, have been performed 
alongside the modifications of the ICL3 for successfully crystallized receptors. One of the 
apparent challenges to crystallizing GPCRs is the destabilization that these receptors experience 
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as a result of the necessary extraction of these receptors from the lipid bilayer with detergents. 
Part of this destabilization occurs because of the loss of lateral pressure that the native membrane 
previously provided the receptor before detergent extraction. This loss results in unfolding and 
aggregation. Several approaches have historically been used to identify the mutations that have 
the greatest contribution to receptor stability. One approach, utilized for the stabilization for the 
turkey β1AR and human adenosine A2A receptors, is to measure the effect of mutations on the 
stability of the receptor in detergent (62, 63). The first step of the method is to pre-incubate the 
receptor with radioligand. After incubation, the temperature is increased so as to denature the 
protein, followed by quenching of the reaction on ice and separating out the remaining ligand-
bound receptor by mini gel-filtration columns. The 3H-labeled ligand signal is measured 
providing a means to identify which thermostabilization mutations have a positive effect on 
protein stability by quantifying the ligand binding activity of mutant constructs (64). 
A method, more commonly used today, is to screen the consequence of mutations on the 
melting temperature of proteins using a fluorescent dye that binds to an unfolded protein. A 
temperature gradient can be used to identify the temperature at which the receptor unfolds. This 
method is high-throughput, as it is adaptable to a Real-Time PCR setup. Though the classical 
melting temperature assay for soluble proteins relied on sypro-orange (65-67) it could not be 
used for GPCRs due to the presence of detergents that increase background fluorescence to the 
point of masking the signal (68). However, the recent application of thiol-specific fluorochrome 
N-[4-(7-diethylamino- 4-methyl-3-coumarinyl)phenyl]maleimide (CPM) allows for the same 
thermo-gradient assay without the high background fluorescence (69). This assay can be used to 
screen for the effect of mutations geared at increasing the melting temperature of the protein, as 
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well as identifying, in a high throughput manner the consequence of crystallography conditions 
on receptor stability. 
Table 1. Approaches to crystallizing multiple activation states of GPCRs 
1.1.3.2 Crystallization of Multiple GPCRs Conformations 
As shown in Table 1, multiple conformations of the Rhodopsin Family have been 
crystallized. Crystallization approaches were initially focused on inactive conformations 
stabilized by the use of antagonists and inverse agonists. Use of ligands as well as modifications 
to the ICL3 were employed to inhibit the constitutive activity of the protein, which made 
crystallizing the receptor more difficult.  
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The first GPCR to be crystallized in an active conformation was the human β2AR in 
complex with an irreversible agonist that was covalently tethered to the receptor through an 
engineered disulfide bond (70). The engineered agonist irreversibly blocks ligand binding.  
Furthermore, excess inverse agonist was not sufficient to affect the irreversible agonist coupling 
of β2AR coupling to GαSβγ (GS). Despite the irreversible nature of the agonist, molecular 
dynamics simulations suggested that the agonist bound conformation would likely relax into an 
inactive-like conformation without an HGP present.  As a result, the next crystal structure to be 
solved employed an approach similar to that of the Fab-ICL3 stabilization. Due to the challenges 
involved in stabilizing the active state of the receptor without HGP present, a nanobody (Nb80) 
(a camelid antibody fragment that lacks the heavy chain) was developed (44). This nanobody, 
which showed G protein like activity, stabilized an active conformation of the receptor in the 
presence of agonist (Figure 5). This results in small changes to the binding pocket, as well as a 
large 11Å movement away from the core of TM6. Changes similar to the active form of Opsin 
(49) were observed in this structure, showing rearrangement of TM5s and 7 as shown in Figure 
5. 
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Figure 5. Comparison of the agonist Nb80 stabilized crystal structures of the β2AR (orange) to 
the inverse agonist carazolol bound β2AR (cyan). 
Within the same year, the structure of agonist bound β2AR in complex with nucleotide 
free GαSβγ was solved. To stabilize this structure, llamas immunized with crosslinked β2AR and 
GαSβγ were used to isolate a nanobody that prevents dissociation of the complex (Nb35). The 
observed structural changes seen in the nanobody stabilized agonist bound β2AR structure were 
highly homologous with those observed in the β2AR-GαS structure with the exception of a 3Å 
movement outward of the cytoplasmic end of TM6 where it interacts with GαS. GαS is made up 
of two domains, the largest being the Ras-like GTPase domain, which is the site of interaction 
with subunits β and γ. The second subunit of GS is the α-helical domain and the border between 
these two subunits of GS makes up the nucleotide-binding pocket. As shown in Figure 6, the 
primary site of interaction between β2AR and GS is with the Ras-like GTPase domain. There is 
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no observed interaction of the β or γ subunits with the receptor. The GαS subunit interacts with 
the ILC2, TM5 and TM6 of the receptor. These observations gave rise to a model of the 
interaction of β2AR with GαSβγ. In this model, the release of GDP is facilitated by agonist bound 
β2AR. This results from the binding of the receptor to the Ras-like GTPase domain. This 
interaction produces a downward movement of the α-helical domain, facilitating a nucleotide 
free state.  
The three conformations of the β2AR solved to date provide exciting insights into the 
functionality of the receptor and the effects of agonists and antagonist on structure and function. 
Furthermore, the surprising structural interface between β2AR and GS may inform further 
biochemical study. In addition to these findings, the development of the techniques that made 
these structures possible may ultimately prove to be as important as the insights the structures 
themselves provide. As illustrated in Figure 1 a representative structure from only one of the 
other GPCRs has been solved, the Secretin family, and these structures are limited to their 
inactive conformations. Applying the successful Family A methods to the crystallography of 
other GPCR families may broaden the array of possible structures that can be solved. These 
techniques may also provide a means to solving structures representing multiple conformations 
of a Family B GPCR.  
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Figure 6. β2AR bound to nucleotide free GαSβγ, stabilized by nanobody Nb35. 
1.1.3.3 Parathyroid Hormone Receptor 1 
The Parathyroid Hormone Receptor Type 1 (PTHR1) is a prototypical Family B GPCR 
with no full length structures yet solved. Applying the now routine approaches to obtaining 
crystals of GPCRs should provide a means to crystallize the PTHR1, a highly useful structure 
due to this protein’s significant pharmacological relevance, 
The PTHR1 binds Parathyroid Hormone (PTH), a key regulator of extracellular calcium 
and phosphate homeostasis, and is essential in the human body’s management of bone healing 
and regeneration (71). When full length PTH (1-84) or its N-terminal fragment PTH (1-34) is 
administered intermediately to patients, bone density is increased, making it a useful 
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pharmacological agent for the treatment of osteoporosis (72).  However, PTH administration is 
limited by the development of hypercalciuria in some patients.  A high-resolution structure of the 
PTHR1 would serve to elucidate the working of this specific pharmacological target and also to 
expand our knowledge of GPCRs beyond the Rhodopsin-like class.  
Major strides were made in understanding the structural-functional interactions of the 
PTHR with its ligand, PTH, in 2008 and 2010 with the publication of the extracellular domains 
structures of naïve and PTH bound PTHR1 (73, 74).  However, with these publications came 
additional mysteries. For example, little was described regarding the interaction of the C-
terminal region of PTH with the juxtamembrane domain of the receptor.  The J domain, which 
includes the extracellular loops and ends of the seven transmembrane α-helices is crucial to 
PTH-PTHR1 activation (75-77).  The J domain was not included in the construct used to resolve 
the ecto-domain structure, so the impact of PTH binding to these regions was not elucidated.  
Furthermore, the conformational shifts required to propagate PTH binding from the extracellular 
domain to the cytoplasmic domain could not be observed without the J domain, even if these 
loops were not essential for binding. Without a transmembrane version of the PTHR1 for 
structural studies, the function of the J Domain is impossible to extrapolate. Applying the well-
established protein modification and crystallographic approaches for Family A GPCRs described 
here in 1.1.3 could provide a means to unravel the unknown structure-function behavior of the 
PTHR as well as further expanding knowledge of the Family B GPCRs. 
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1.2 STRUCTURAL BIOLOGY APPROACHES TO UTILIZING CRYSTALS FOR 
STRUCTURE DETERMINATION 
1.2.1 Protein Crystals as the Backbone of High-Resolution Structures.  
As proteins grow into a solid structure from purified protein in solution, a crystalline 
lattice made up of protein molecules in a specific and regular orientation, is constructed from the 
unit cell, or the fundamental unit of the crystal. The collection of symmetry operations that can 
generate the complete crystal lattice from the contents of the asymmetric unit is known as the 
space group. When crystals are grown to adequate size and quality they become useful for X-ray 
crystallography experiments. The electron clouds surrounding atoms in the crystal diffract X-
rays according to Bragg’s Law to produce a diffraction pattern. Analysis of the position and 
intensity of each diffracted wave (reflection), along with its phase, when the angle of the X-ray 
beam to the crystal is taken into account, can be used to obtain a map of the electron density 
within the crystal and, ultimately, a model of the protein structure that generated the diffraction 
pattern, provided sufficiently high resolution data are obtained. 
There are several approaches to obtaining structural information from these well-ordered 
crystals. Classical, large crystal X-ray crystallography, which was used to solve the above-
mentioned GPCRs, is currently the most commonly used approach to structural resolution of 
large proteins. However, there are two other methods that have been successfully applied to these 
difficult-to-obtain crystals. Nanocrystals of a GPCR have also been used to solve structures from 
X-FEL (78). Cryo-EM has also has been used to facilitate structure solution of bacteriorhodopsin 
by combining cryo-EM data with data obtained from crystals grown in the lipidic cubic phase 
 18 
and analyzed by X-ray crystallography (79, 80). Each of these approaches provides different 
advantages and disadvantages for successful structural solution. 
1.2.1.1 Identifying Conditions for Promoting Crystals Growth 
 
The aim of crystallization methods is to obtain a slowly developing supersaturated 
protein solution such that protein nuclei are able to grow into large, well ordered, and usable 
crystals. To identify the conditions that promote supersaturation and stable crystal growth, 
crystallization trials aimed at systematically screening a myriad of conditions that include salt 
concentration and type, pH, temperature, cross-linking agents and chemical additives that will 
promote crystal growth are performed. Unfortunately, though a systematic approach to screening 
conditions is possible, the infinite combination of available selections requires human 
interpretation of subtle signs and symptoms of potentially favorable conditions.  
There are many approaches that are commonly used to identify crystallization conditions 
for a given soluble protein. These same approaches are the initial starting point for the 
crystallization of detergent solubilized membrane proteins, though there are many other 
techniques available when those fail. The first line of attack to finding these conditions is to 
screen with commercially available kits. These screens provide pre-prepared concentrations and 
combinations of salts, pH, chemical additives, and different molecular weight PEG, to name a 
few. These matrix-screening approaches do not contain every possible crystallization condition, 
but they may give some clue as to the best approach for optimizing protein-specific 
crystallization conditions. The greatest utility of these commercially available screens is to 
enable rapid screening of a wide range of crystallization space with standardized and easily 
reproduced stock chemicals. 
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1.2.1.2  Methods for Optimization 
The first stage of crystallization experiments aims to identify conditions that promote 
crystal nucleation and growth. However, in many, if not most cases, the initial conditions 
identified are not sufficient for the growth of high quality, large crystals. As a result, it is 
necessary to optimize crystallization conditions in order to grow the best possible crystals and 
thus maximize the diffraction by the crystals. The primary approach to optimization is to note all 
conditions that yield the initial crystal hit – salt type and concentration, pH, temperature, etc. as 
well as protein concentration. These hits refer to crystallization conditions that contain visible 
crystalline precipitate or large crystals. Then systematic and incremental modifications of these 
conditions must be made until changes in crystal growth can be identified, either in the positive 
or negative direction. Pursuit of those changes that favor increases in crystal quality and size is 
the first line approach to crystal optimization.  
In some frustrating cases however, this approach does not rapidly yield helpful changes 
in crystal quality. In this case there are several other approaches that can be utilized. One is the 
use of libraries of highly concentrated additives that are used to supplement the initial (or 
optimized) crystallization condition hit. These additives impact crystal growth by changing 
protein solubility, modulating protein-protein interactions, and altering the thermodynamics of 
the precipitation process. One approach is to screen a small molecule library that is added to the 
crystallization condition being optimized. Detergent screening is performed in a similar manner 
and can be used to reduce non-specific aggregation that can limit crystal growth. Ionic liquids are 
organic salts that are highly soluble and can take part in ionic, hydrophobic and hydrogen 
bonding (81). These chaotropic liquids have been shown to reduce aggregation as well as 
enhance protein folding (82, 83). Ionic liquids can be screened as additives by the same method 
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mentioned above. In addition to studying the effects of these additives on crystal size and 
morphology, high throughput additive screening can also be coupled to the above mentioned 
(section 1.1.3.1) thermal shift assay. This approach will provide a quantitative means to compare 
the effect of the various additives on protein melting temperature. 
Seeding is another long-standing optimization tool in the crystallographer’s arsenal. This 
technique consists of three main approaches. Macroseeding traditionally refers to the process of 
transferring a small crystal or crystal fragment into a series of stabilizing wash solutions. After 
washing, the small crystal is transferred into a pre-equilibrated drop in order to grow the crystal 
larger (84, 85). Microseeding involves removing crystals from a drop, transferring them into a 
stabilizing solution, crushing them, and then creating various seed stocks by performing serial 
dilutions of the crushed crystal seeds (86, 87).  Seed solutions are then introduced into new drops 
in the hope that the tiny crystal seeds will promote the growth of larger or more ordered crystals. 
In both instances the aim is to take microcrystals or fragments from large crystals and seed them 
into a metastable supersaturated protein drop to provide nucleation sites while controlling 
growth.  
The third approach to seeding is microseed matrix screening (MMS), which is becoming 
a popular technique due to its adaptability to robot crystallization tray setup (88, 89). MMS is 
performed by first setting up traditional commercially available screens and then subsequently 
identifying crystals hits, likely of poor quality, to use as seeds. Low quality crystal hits are 
homogenized, pooled, and the resultant seeds are added to a new set of screening experiments, 
using the same screen from which the seeds were extracted. The challenge for this technique 
however is to adequately separate useful seeds from those that will have a deleterious effect on 
attempts to obtain higher quality crystals or are simply from a salt source that is indistinguishable 
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from protein. Furthermore, this technique has only been proven useful with visible crystals and 
does not utilize precipitates. 
1.2.1.3 Special Considerations For Crystallizing GPCRs 
The above-mentioned techniques can be used for crystallizing both soluble, membrane 
and multi-protein complexes. However, because of the unique difficulties in crystallizing large, 
seven transmembrane proteins, several different methods have been developed or expanded upon 
to crystallize these receptors. GPCRs can be crystallized from detergent (62). However, a far 
more effective technique for GPCR crystallization is crystallizing in lipidic cubic phase (LCP) 
(90). The development and application of this technique led to the first high-resolution structure 
of bacteriorhodopsin (91, 92). This viscous lipid solution forms a continuous bilayer in which 
protein can freely diffuse. The protein crystal nucleation sites that the three dimensional bilayer 
provides are fed by the freely diffusing protein (90). A similar technique that has been applied to 
GPCRs avoids some of the technical challenges of working with the viscous LCP medium is 
crystallization in bicelles (53). Bicelle crystallization provides a compromise between lipid and 
detergent by forming a lipid/amphiphile mixture, integrating detergent molecules into lipid 
bilayers (93). This technique provides several advantages including being amenable to different 
combinations of lipid types and detergent (94).  
1.2.2 Methodological Approaches to Solving Structures from Protein Crystals 
There are three main approaches to solving structures of ordered, three-dimensional 
crystals. X-ray crystallography is the most commonly applied and perhaps the most well-
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developed approach to solving structures of proteins that can be coaxed into well-ordered 
crystals. A long-standing technique, this method requires, in most instances, micron sized 
crystals to solve structures. This field has contributed to the development of several areas of 
crystallography. It has provided a systematic approach to obtaining protein crystals described in 
previous sections, as well as establishing screening methods to identify cryoprotectants. The 
science of X-ray crystallography has also lead to the development of automated computerized 
techniques for translating a full data set into an electron density map suitable for building and 
refinement of high-resolution structural model. However, though X-ray crystallography is the 
primary approach to utilizing crystals, other techniques including X-ray free electron laser 
nanocrystallography and transmission electron microscopy can make use of crystals of much 
smaller size, thus overcoming some of the limitations of X-ray crystallography. 
 
1.2.2.1 X-Ray Free Electron Laser Nanocrystallography 
X-ray crystallography is a powerful tool to solve high-resolution structures of proteins; 
however, it comes with many disadvantages that limit its scope. The most apparent limitation is 
the unpredictable nature of finding conditions that yield large diffractable crystals. For many 
difficult targets, such as GPCRs, only microcrystals of these proteins can be obtained. The 
development of microfocused beamlines, however, have made it possible to solve structures 
from these smaller crystals (95). This development has been particularly essential for GPCR 
crystallography, as several notable GPCR structures could be solved solely using merged data 
sets from numerous microcrystals (96). In addition to being able to use smaller crystals that 
cannot be optimized to greater size and quality, collecting on microcrystals may provide benefits 
when twinning or mosaicity are a limiting factor (97). However, data collection on microcrystals 
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is not simple, and challenges such as high background and significant radiation damage may 
limit structure resolution (98).  
However, the introduction of X-ray free electron lasers (X-FEL) overcame many of these 
challenges. X-FELs are up to ten times more brilliant than modern day synchrotrons (99). The 
diffract-before-destroy principle, applied at Linac Coherent Light Source’s (LCLS) Coherent X-
ray Imaging (CXI) beamline allows for the high energy XFEL to hit a single nanocrystal, under 
ideal conditions, to produce a single diffraction snapshot before the nanocrystal is destroyed. 
Theoretical and experimental results demonstrate that this diffract-before-destroy technique 
almost completely avoids radiation damage, solving the problems associated with collecting data 
on small crystals at a microfocus beamline (100).  
The brilliant light source provided by LCLS yields opportunities for solving structures of 
challenging targets using small crystals. However, there were, and still are, many difficulties to 
be overcome in this field. The initial hurdle inherent to the diffract-before-destroy principle was 
sample delivery. Since only a single diffraction pattern could be collected per crystal, single 
crystals mounted on individual loops would not be practical for data collection. The first 
approach to overcome this challenge was a nanocrystal liquid injection system (101). This 
injection system directed a stream of nanocrystals of sufficient volume directly into the X-FEL 
beam, synchronized with the beam pulse.  
Use of X-FEL technology provided a means to use nano and microcrystals too small for 
use even on a microfocused beamline or too vulnerable to radiation damage. Since many 
crystals, particularly GPCRs, have few crystal hits that can be optimized into large crystals 
appropriate for traditional X-ray crystallography, a new set of targets can now be studied. 
However this technique, though powerful for nano- and microcrystals, has only been applied to 
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samples that have previously been shown to grow to large sizes. Further investigation is 
necessary to develop techniques for identifying and testing nanocrystals that could not be 
optimized sufficiently for X-ray diffraction experiments by conventional synchrotron sources. 
1.2.2.2 Electron Microscopy 
Transmission electron microscopy (TEM) is a technique useful for obtaining structural 
details of biological macromolecules to a resolution of 0.1 to 0.2 nm. The TEM microscope is 
composed of a metal column under vacuum in which a linear beam of electrons is accelerated 
and focused by electromagnetic and electrostatic manipulation. Electrons are commonly 
generated by heating a tungsten filament, leading to evaporation of electrons from the filament.  
The voltage potential between the cathode emitter and the positively charged anode plate 
accelerates the electrons down the column.  Electrons that pass through an aperture in the anode 
plate and the specimen are focused to form the image of the sample on a phosphorescent screen 
or CCD.  
Examination of specimens by TEM has the advantage of requiring low concentrations of 
materials. In order to view samples such as protein or nanocrystals, these biological 
macromolecules must first be applied to a fine mesh grid, commonly made of copper with a 
carbon support film. These hydrophobic grids are glow discharged to make them hydrophilic 
before the sample is applied. To enhance the visualization of protein samples, a heavy metal salt 
such as uranyl acetate is used to stain sample-containing grids. The uranyl acetate will occupy 
hydrated regions in and around the protein sample, only staining the background and leaving 
protein looking white and unstained. A modified TEM approach, cryo-TEM, allows for the study 
of samples without the use of staining, dehydration, and fixation that the sample undergoes 
during negative stain TEM. Cryo-TEM samples are rapidly frozen to cryogenic temperatures 
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where water can exist in a vitrified state, keeping the sample hydrated. This allows for viewing 
of samples in a more native-like environment than traditional negative staining. 
In addition to the visualization of samples, TEM provides a means to perform electron 
diffraction experiments to solve structures utilizing crystals much like X-ray crystallography. 
Cryo-TEM makes use of nanocrystals to solve structures by utilizing the advantages that 
electrons provide over X-rays. The advantage of electron diffraction for thin specimens over X-
rays is that the damage per elastic event for X-rays is more than one hundred times greater than 
for electron diffraction, allowing for more data to be collected before the crystal is made 
unusable by radiation damage (102). Initially, this allowed for the resolution of structures using 
TEM initially performed on 2D crystals (103, 104). However, an extensive number of crystals 
must be used to provide sufficient data in order to solve structures. These large volumes are 
required because of the significant radiation damage that the crystal undergoes which only 
allows for a single diffraction pattern to be obtained per crystal (105).  In response to these 
challenges there have been recent methodological advances that utilize a significantly lower 
quantity of 3D crystals for solving structures (106, 107). The new technique relies on using a 
particularly low electron dose to prevent radiation damage to 3D crystals, overcoming the 
challenges associated with 2D crystal data collection. This provides a means to use a much 
smaller volume of crystals for solving structures than was previously possible (107).  This 
method has been demonstrated in a recent paper using lysozyme nanocrystals as a model system 
(107). Use of 3D crystals in diffraction experiments necessitated thin preparations of lysozyme 
crystals where only crystals between a thickness of 0.5-1 µm and 1-6 µm long were usable for 
data collection. Electron diffraction was used to collect data on these crystals using a tilt-series 
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that allowed for the collection of 90 different diffraction patterns per single crystal. Collecting in 
low dose mode enhanced the data set collected for a single crystal, minimizing radiation damage. 
Although this technique expands the possibilities for solving structures from nanocrystals 
by cryo-TEM, it has yet to be used for proteins for which larger crystals could not be obtained or 
for proteins that require nanocrystal optimization in order to get the best possible diffraction 
data. Furthermore, as demonstrated in the recent tilt-series paper using lysozyme, growing and 
then subsequently identifying nanocrystals of ideal size can be difficult, requiring further work to 
make this approach more applicable to other protein nanocrystals. 
1.3 CONCLUDING REMARKS 
There are powerful tools available to structural biologists for solving structures of large, 
challenging targets. These tools include well-established, robust techniques, such as X-ray 
crystallography, as well as newer strategies such as X-FEL nanocrystallography. A group of 
targets that have long been considered classic examples of difficult targets are the GPCRs. 
Though 19 unique structures have been solved for the largest of the GPCR families, little is 
known of how to solve and resolve structural features of other GPCR families. It is expected that 
the classical protein modification and crystallography techniques developed for obtaining 
crystals and solving Family A GPCRs will be readily applicable to other families. However, 
given the low sequence homology amongst GPCR families, this may not be a foolproof way to 
obtain structures. The PTHR1 is an example of such a challenging target whose structure would 
elucidate a significant pharmacological target, highly useful for osteoporosis interventions. 
Family A protein modifications and crystallography optimization tools will be the first line of 
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attack applied in the work presented here to obtain usable crystals of the PTHR1. However, since 
the inherent difficulties of working with GPCRs are further complicated by the PTHR1 not being 
a member of Family A, other methods for growing, identifying, optimizing and utilizing crystals 
will be employed. In addition to the pharmacological significance that this target represents, it is 
also an ideal candidate for developing methods applicable to other previously unsolvable 
challenging targets. This work strives to compare and utilize X-ray crystallographic, TEM and 
nanocrystallography techniques for obtaining crystals of difficult targets using the PTHR1 as a 
suitably challenging test case.  
1.4 AIM AND HYPOTHESIS  
Central Hypothesis:  
Protein nanocrystals can be identified in a variety of protein targets intended for crystallization 
experiments, including samples of soluble, membrane and multiprotein complexes. 
 
Specific Aim 1:  
Perform crystallization trials of the PTHR1 using previously established Family A GPCR 
strategies 
 
Specific Aim 2:  
Identify protein nanocrystals of PTHR1 and other challenging targets by TEM  
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Specific Aim 3:  
Use TEM to evaluate the consequences of the X-FEL Gas Dynamic Virtual Nozzle injector on 
nanocrystals morphology 
 
Specific Aim 4:  
Compare the crystal optimization potential of conventional seeds to TEM visualized “nanoseeds”  
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2.0  PTHR1 CRYSTALLIZATION TRIALS 
2.1 INTRODUCTION 
Structural biologists have made exciting progress in the understanding of the structure and 
function of Family A GPCRs. This progress is mainly due to the ever-expanding catalogue of 
unique GPCR crystal structures as well as the recently solved multiple conformations of β2AR. 
However, much is still unknown about the Family B GPCRs as a result of the lack of high-
resolution structures. This challenge has only recently been overcome with the crystal structures 
of the glucagon and corticotrophin-releasing factor receptor 1 (108, 109). The recent crystal 
structures were not full-length constructs and were truncated to exclude their large N-terminal 
domains. The lack of information is significant, as some of the most important differences 
between GPCR families are traced to the variations in the type of extracellular domains that are 
found in the N-terminus. 
 Many of the soluble ECD domains of the Family B GPCRs have been crystallized 
individually (73, 74, 110-112). For example, the prototypical member of the Family B GPCRs, 
the parathyroid hormone receptor type 1 (PTHR1) is illustrated in Figure 7 with the bound 
parathyroid hormone (PTH).  As seen in this figure, the parathyroid hormone (PTH) is 
sandwiched between the N-terminal helix and the C-terminal β-sheet of the PTHR1 extracellular 
domain (ECD). A comparison of the ligand bound (Figure 7A) and naive ECDs (Figure 7B) 
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suggest that when the ECD is without ligand, it dimerizes with itself.  However, in vivo assays 
have yet to support this result and demonstrate the biological relevance of the dimerization.  
Further understanding of the PTHR1, in vivo, would be valuable in determining useful 
crystallographic approaches to solving the structure of full length PTHR1. 
Figure 7. Crystallized extracellular domains of the PTHR1 
As illustrated in Figure 8, the PTHR1 contains many of the same flexible domains that 
interfere with crystallization in the Family A GPCRs as illustrated with a predicted disorder plot 
of β2AR. More disordered regions, with a greater degree of disorder, are predicted for the 
PTHR1 compared to the β2AR. Specifically, both the N-term and C-term of the PTHR1 are 
longer and have greater disorder.  One could presume, however, that similar regions of instability 
(e.g. the third intracellular loop (ICL3) and C-term tail), would be amenable to the same 
crystallographic strategy that has been successful for the Family A receptors. 
A) Monomeric ligand bound ECD versus B) the apparent dimeric ECD structure without ligand.
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Figure 8. Predicted disorder of the PTHR1 versus β2AR generated by DISOPRED2 
In addition to the hurdles presented by stabilizing the numerous disordered regions of the 
receptor, the requirements unique to successful membrane protein crystallization also provide 
formidable challenges. This requires careful screening of conditions that best stabilize the 
extraction and monodispersity of a purified membrane receptor. Furthermore, these conditions 
need to be optimized to allow for maintaining the functional activity of the protein outside of its 
natural environment--the conditions of which may not be ideal for solubilization. 
The aim of this work was to test the applicability of the successful Family A GPCR 
protein modifications and crystallization approaches to obtaining crystals of the PTHR1. Given 
the lack of full-length structures of the Family B GPCRs, crystallization constructs with the ECD 
were used for these trials. Furthermore, structural knowledge of the receptor, provided by the 
ECD structures with and without ligand, illustrates the presence of crystallization-adverse 
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flexible portions of the soluble ECD component of the receptor. This information was also used 
to guide the design of constructs.   
2.2 RESULTS 
2.2.1 Development of a Protein Purification Protocol for the PTHR1 
An E. coli expression system was chosen for the PTHR1 due to its high yield, ease of expression 
of PTHR1 mutants and the comparative lack of post-translational modifications, which confer 
crystallographic complications. Since receptor glycosylation has been demonstrated to be 
unnecessary for ligand binding (113), post-translational modifications were deemed unnecessary. 
The human PTHR1 was cloned into a pET21a vector with a C-terminal 10xHis tag. 
A 96 detergent dot blot screen (Hampton Research) was performed which included ionic, 
non-ionic and zwitterionic dispersing agents in order to extract the maximum amount of 
recombinant protein from the E.coli expression system.  To perform this screen, the PTHR1 was 
expressed in large scale. Isolated cells were lysed by sonication and aliquoted into 0.5 mL 
fractions. The insoluble membrane pellet was isolated by centrifugation and each fraction was 
homogenized with a member of the detergent screen, excluding controls, at approximately 2.5 
times the critical micelle concentration (CMC). Solubilized fractions were applied using a dot 
blot apparatus to a nitrocellulose membrane. The membrane was blotted with an anti-His probe. 
Promising solubilizing agents resulted in dense signals in the dot blot as shown in Figure 9. The 
darkest dots indicate well-extracted protein, while the bottom right dots mark the controls, with 
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barely any visible extracted protein. This assay indicated that a combination of Sarcosine and 
Fos-choline 14 were the best solubilization agents for the PTHR1. 
Figure 9. Nitrocellulose membrane exposed to PTHR1 extraction samples using a dot blot 
apparatus, probed with anti-His 
To determine the most appropriate agent combination and concentration to promote a 
monodisperse sample, dynamic light scattering (DLS) experiments were performed. As 
illustrated in Figure 10, submicromolar concentration of Fos-choline 14 resulted primarily in a 
one species decay. Following these small-scale experiments, large-scale purification the PTHR1-
His was performed using a Ni-affinity chromatography, followed by a desalting column to 
remove imidazole.  Purification yielded 1.5 mg purified protein per 1 L of cells as shown in 
Figure 11. 
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Figure 10. Autocorrelation function versus time of purified PTHR1 shows primarily one species 
decay 
Figure 11. Purified PTHR1 with a predicted molecular weight of 66 kDas stained with Bradford 
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2.2.2 Interaction of purified PTHR with PTH 1-34 and GS 
To test the functional activity of purified PTHR1, the receptor’s ability to interact both 
with its extracellular ligand and with its intracellular binding protein was investigated. To 
determine if purified protein was able to bind to both ligand and to its intracellular binding 
partner, GαSβγ, on-column binding experiments were performed. As illustrated in Figure 12A, a 
biotinylated PTH 1-34 analog was incubated with receptor and subsequently mixed with 
streptavidin beads. As shown in Figure 12B, the PTHR1 is able to bind to bio-PTH 1-34 and be 
retained on the beads, while PTHR1 not incubated with bio-PTH 1-34 was not retained.  
Figure 12. PTHR1 binding to biotinylated PTH 1-34 
The second on-column experiment tested the ability of purified receptor, bound to PTH 
1-34, to interact with its intracellular binding partner GαSβγ. His-PTHR1 was incubated with 
untagged GαSβγ and passed over a Ni-resin column. As shown in Figure 13A, the PTHR1 
receptor is retained, along with GαS, while very little Gβγ is still present (Gγ is not visible due to 
its small size).  Gβγ washed out, as visible in the flow through lane. A model of this interaction is 
shown in Figure 13B. This model is very similar to that observed in the recently resolved β2AR-
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Gα complex structure (45). This structure shows that in the presence of ligand, the only crystal 
contacts with GS are with GαS, while none are observed with Gβγ.  These on-column 
experiments show an interaction between purified receptor and extracellular ligand as well as 
with the intracellular binding partner, GαS. After optimization, these binding interactions were 
not inhibited by the detergent type or concentration used for solubilization of the receptor.  
Figure 13. On column PTHR1-GS binding experiments 
2.2.3 Crystallization Trials with Wild-Type PTHR1 
Crystallization trials were performed with the purified, solubilized receptor. As described 
in section 1.1.3.2, the presence or absence of ligand has significant effects on the crystallization 
strategies required to obtain the Family A GPCR crystals. Therefore, crystallization trials of the 
PTHR1 were performed with PTH 1-34 and with PTH 1-15, the most readily available 
antagonist of the PTHR, as well as trials with no ligand present. 
His-Tagged PTHR1, GαSβγ and PTH 1-34 were incubated together, shown in the “Load” lane. The “Load” was 
applied to a Ni-affinity column and “Flow thru” collected. The PTH 1-34-PTHR1-Gs complex was then eluted 
with imidazole
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Crystallization experiments of the monodispersed receptor in the presence and absence of 
ligands were first approached using traditional, commercially available kits. Screens were 
obtained from a variety of manufactures including Hampton Research, Molecular Dimensions 
and Emerald Bio. These screening experiments were performed at 4°C, 16°C, 25°C. No visible 
hits were detected.  Drops containing useful protein aggregates were identified by UV tryptophan 
fluorescence microscopy.  Up to one third of drops screened had fluorescence.  
Several different optimization strategies were pursued for the purpose of transforming 
UV positive precipitates into visible microcrystals. As a first step, conditions that yielded useful 
precipitates of wild type PTHR were set up using increments of the modified component of the 
crystallography experiment that were slightly (or dramatically) changed. For example, the 
concentrations, pHs, PEG types and temperature were modified.  None of these efforts resulted 
in useful, visible crystals. Lipidic cubic phase (LCP) trials with crystallography screens 
specifically compatible with LCP were used in testing. Moline LCP and well as Moline + 
cholesterol LCP were setup for the receptor with and without ligands. Bicelle crystallization with 
different lipid combinations were also tested. Furthermore, ‘in gel’ agarose experiments were 
performed using the same commercially available screens employed in the original PTHR1 
screening. 
In addition to these efforts, modifications of seeding protocols were also performed using 
drops containing granular aggregates that were positive for UV tryptophan fluorescence (rather 
than the traditional use of low quality visible crystals). These experiments include collecting UV 
positive aggregates and performing streak microseeding and MMS experiments. A type of cross 
seeding was also applied, in which PTH 1-34 crystals were seeded into crystallography 
38 
experiments. Despite these attempts at crystallizing the full length PTHR, the receptor was not 
amenable to crystallization efforts in its native form. 
Table 2. PTHR1 crystallography mutants 
As a result of the lack of success with crystallization trials, crystallographic protein 
modifications, in line with those that have been successful with the Family A GPCRs, were 
tested.  The goal was to create truncation fragments that reduced the effect of disordered regions 
in the PTHR. Table 2 summarizes the protein modifications that were applied to the PTHR1. The 
most nascent modification was to remove the flexible C-term tail to amino acid 480, a 
modification that retains the functional activity of the receptor.  This modification was combined 
with replacement of the ICL3 flexible domain with a rigid Ser-Gly linker. A similar technique 
was used to stabilize the ICL3 of the turkey β1AR construct used for crystallization of the 
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receptor (61). Crystallization trials with these modified proteins did not provide useful crystal 
hits, and no improvements were observed over time in crystal trays.  
One potential source of the continued inability to obtain hits was the possible negative 
contribution of the large ECD of the receptor. The crystal structures of the ECD clearly show a 
45 amino acid flexible loop, which though included in the construct, could not be resolved in 
either structure (Figure 14A). To mediate the impact of this loop on the crystallization trials, it 
was removed and replaced with a rigid serine glycine linker modeled to maintain the distance 
between the α-helix and β-sheet. These modified ECD constructs (referred to as K truncation 
mutants) were made with full-length C-term tail, 480 stop and 480 stop + ICL3D. Interestingly, 
despite a significant modification to the ECD region, the application of ligand to pure K-PTHR1 
still resulted in the typical disruption of oligomerization previously observed in the ECD crystal 
structures (Figure 15) (74, 114). However, as in previous trials, no significant changes in 
crystalline hit number or quality were noted.  
Figure 14. The PTHR1 extracellular domain structure, which reveals a 45 AA, disordered loop, 
replaced in tested crystallization constructs with a 8 AA stabilizing Ser-Gly linker 
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Other truncations were performed, such as complete removal of the ECD of the receptor 
and point mutations to obtain constitutively inactive and active PTHR1 mutations. Problems, 
however, such as low expression for crystallization trials or rapid protein degradation made such 
mutants unsuitable for crystallization trials. As a result, on the 480s, ICL3D and K mutants (as 
well as combinations of these truncations together) were tested. 
Figure 15. Effect of PTH (15-34) on KPTHR480S aggregation 
Though the initial aim of this work was to obtain visible crystals of the PTHR1, the lack 
of positive effect of the previously successful GPCR crystallization modifications was curious. 
The contribution of these mutations to the overarching stability of the truncation mutant melting 
temperature (Tm) was evaluated by Microscale CPM Assays. This assay, described in section 
1.1.3.1, relies on CPM, a fluorescent dye that is quenched in aqueous solution but fluoresces 
when bound to exposed cysteine residues. This dye can be used to screen the consequence of 
mutations on the melting temperature of the protein using a temperature gradient to identify the 
temperature at which the receptor unfolds, as indicated by an increase in fluorescence.  
The first investigation using this Thermofluor assay was carried out with full length 
PTHR1 to compare the stability of the receptor in the presence and absence of ligand across 
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variations in pH typically present in crystallization experiments. As indicated in Figure 16, PTH 
1-34 decreased melting temperature only slightly and did not modify the overall trend of PTHR1 
stability over increasing pH. This correlates with the lack of observable improvement in crystal 
hits in initial screening with wild-type PTHR. 
Figure 16. Melting temperature of full length PTHR1 when exposed to increasing pH 
The Microscale CPM Assay was subsequently used to compare the PTHR1 constructs 
used for crystallography trials. As demonstrated in Figure 17 the basic modifications that 
focused on the obvious disordered regions of the PTHR1 had surprisingly deleterious results, 
with only an insignificant increase in Tm by the ICL3 deletion construct. The effect of ligands on 
the Tm of the truncation mutants was also examined.  Both agonist and antagonist were able to 
increase the Tm up to 7°C. However, even the ICL3 deletion construct with its increase in Tm 
gained by antagonist fell short of that conferred to full length PTHR1. 
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Figure 17. Change in relative Tm of PTHR1 mutants compared to full length in the presence of 
agonist, antagonist and in the absence of ligand. 
2.3 DISCUSSION 
A high yield of monodispersed PTHR1 was expressed and isolated from E. coli. The 
purified, recombinant protein was able to bind ligand as well as its intracellular binding partner, 
providing an excellent starting point for crystallization trials. GαSβγ binding experiments showed 
interesting similarities to the binding interactions observed in the recently solved β2AR-Gs 
complex (45). This structure showed that the only contacts between the receptor and Gs were 
with the Gα subunit. Similarly, purified His-tagged PTHR1 retained, almost exclusively GαS 
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while Gβ was shown to dissociate from the complex and wash out in the flow through (Figure 
13). 
Crystallization trays of PTHR1 were set up with and without agonist and antagonist. 
These initial trials, at best, only produced UV positive granular aggregates with no visible crystal 
hits—an anticipated result given the difficulties associated with crystallizing GPCRs.  Truncation 
mutants of the PTHR were cloned and purified in order to remove the predicted disordered 
regions. The results of both crystallography experiments and Microscale CPM experiments 
suggest that, unlike the Family A GPCRs, the PTHR1 melting temperature is actually reduced by 
the typical truncation approaches that were successful in the crystallization of previous GPCR 
structures. 
There are several possibilities as to why removing the disordered regions of the receptor 
contributed to a reduction in melting temperatures. The first major modification was to the ECD, 
where the flexible loop of the ECD was removed and replaced by a rigid linker that was modeled 
to maintain the distance between the β-sheets and α-helix. This was the most deleterious of the 
truncations constructs (removing 45 number of amino acids), even though it displayed the same 
monomer/dimer behavior in the presence and absence of antagonist as the constructs used to 
successfully crystallize the PTHR1 ECD. Furthermore, PTH 1-34 and 15-34 both increased the 
melting temperature towards that of the full-length construct. It is of course possible that for 
unforeseen reasons, the removal of this loop actually increased the disorder of the ECD. The 
two-step model of PTH interaction with receptor may provide an explanation for how this 
disorder may have been alleviated by ligands (77). In this model the PTH 15-34 C-term segment 
interacts with the binding pocket of the ECD while the N-term portion (PTH 1-14) of the ligand 
interacts directly with the juxtamembrane region (J domain) of the receptor, comprised its 
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extracellular loops. Perhaps the disorder introduced by the removal of the ECD loop was 
partially stabilized by the ligand if the ligand could act to facilitate the interaction of the ECD 
with the body of the TMD.  
Amongst all GPCRs solved to date, overcoming the challenges of intrinsic basal activity 
that are inherent to these receptors, required the use of specially engineered antagonists that 
forced the GPCR into a lower energy, inactive conformation. Crystallization of these receptors 
with agonists was impossible without other interventions such as nanobody stabilization of the 
active state of the receptor (44).  However, in the case of the PTHR1, it was surprising to 
consider that both agonist and antagonist had similar effects on melting temperatures, and in both 
instances, the result was an increase melting temperature. It is possible that this similar effect on 
receptor stability, observed across all the truncation constructs tested, maybe a result of the two-
step ligand binding model, which closes the ECD towards the receptor. No matter the 
contributing factors, this discovery may give tentative hope that PTHR1 may be more amenable 
to crystallization of both inactive and active conformation than previously encountered by GPCR 
crystallographers.   
Given the lack of Family B crystal structures at the time of this work the truncation 
protein modifications used for this study followed the approaches that had been successful for 
the Family A GPCRs. However, all but one truncation construct, with a Tm change less than 1°C, 
lowered melting temperatures compared to full length PTHR1. This was quite unexpected given 
that the truncation of the C-term tail, for example, is a common necessity in Family A 
crystallization. Given these results, it is not surprising that the two recently solved Family B 
GPCRs show a significantly different approach to crystallizing these receptors than was used for 
the Family As. For example, in both the glucagon receptor (GCGR) and corticotropin releasing 
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factor receptor (CRHR1) efforts towards stabilizing intracellular loops were focused on the ICL2 
and not on the ICL3 (108, 109). Furthermore, as the recently solved structures of GCGR and 
CRHR1 receptors indicate, there are momentous variations between structures within the Family 
Bs. Though the GCGR had the same basic 7 transmembrane α-helix domain orientation of the 
Family As, the CRHR1 has a distinct V shape orientation not observed for other GPCR 
structures. It was hypothesized that the open orientation of the extracellular facing side of the 
receptor accommodates its peptide ligands (109). The differing behavior of the PTHR1 upon the 
application of the Family A GPCR crystallization recipe may suggest that the PTHR1, like the 
GCGR and CRHR1, emulates the same variation that exemplifies the structural differences 
within this family as well as between the other families of GPCRs.  
Given the newly available information provided by the GCGR and CRHR1 structures, 
the course of further crystallization experiments with the PTHR1 could be modified to include 
the successful approaches used for these Family B members. One example would be focusing on 
stabilizing the ICL2 rather than the ICL3 as was done in these two structures. Additionally, 
screening of large fusion proteins to the ECD domain of the receptor (or to a receptor with the 
ECD completely removed) could provide a means to obtain crystals. However, such an approach 
is not trivial and requires screening of large libraries of fusion proteins, as was the case in the 
GCGR. Another consideration brought to light by these new structures is the differences in the 
C-terminal truncations required for crystallization of CGCGR and CRHR1. Both truncated the 
C-terminal tail, but in the case of GCGR, the putative α-helix 8 was retained while CGCGR 
crystallization required complete removal of this helix. The C-terminal truncated PTHR1 
constructs used in this study were truncated at residue 480, allowing for the inclusion of helix 8 
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(contained within residues 465-474). Deletion of this helix, given that it required complete 
removal in the case of CGCGR, may be another useful strategy for crystallization of the PTHR1. 
 Though visible crystal hits were not observed during PTHR1 crystallization, the receptor 
provided an abundance of UV positive granular aggregates. Such aggregates may be ideal 
candidates for nanocrystallography trials, if a way was devised to distinguish between granular 
aggregates that contained nanocrystals suitable for further optimization and X-FEL diffraction 
versus unusable amorphous protein aggregates. If such evaluation were possible, an alternative 
approach to solving structures of GPCRs, perhaps even one that would require less truncation of 
the receptor, would be a powerful crystallographic tool for resolving structures of challenging 
targets such as the PTHR1. 
2.4 METHODS 
2.4.1 PTHR1 Cloning and Expression 
The full-length human PTHR1 sequence was amplified and subcloned into a modified pET21 
bacterial expression vector (EMD Biosciences) with a N-terminal 10x His tag using EcoR1 and 
XhoI restriction sites. Truncation of the C-terminal PTHR tail was performed by inserting a stop 
codon into the sequence at residue 480. Site directed mutagenesis for the Jansen's metaphyseal 
chondrodysplasia, and chondrodysplasia Blomstrand type mutations was directed at H223R and 
P132L respectively, and performed per manufactures instructions with a QuikChange II Site-
Directed Mutagenesis Kit. (Agilent Technologies). Round the Horn PCR was performed both to 
replace the ICL3 (residues 389-401) with a 8 residue rigid Ser-Gly linker as well as to do the 
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same so as to create the K construct, which replaced the extracellular domain flexible loop (59-
105) with the rigid linker. N-Terminal MBP constructs were generated by inserting amplified 
PTHR1 into a MBP pET41 vector using EcoRI and XhoI restriction sites. 
2.4.2 Dot Blot Detergent Screening 
To determine ideal solubilization conditions for the PTHR1, dot blot detergent screening was 
performed. Bacterial lysates were obtained after brief sonication, cell lysates were aliquoted in 
100 fractions containing 100 μL of cell lysate each, and spun down for 30 min. After 
centrifugation, the supernatant was removed and each pellet containing the insoluble target 
protein was re-suspended in 75 μL of buffer A plus 25 μL from each detergent in the 96-well 
format Hampton Research (HR) screen, leaving four control samples for re-suspension with 
buffer only. Since most detergents in the screen were 10�x CMC (for each detergent), aliquot 
detergent concentration was approximately 2.5 x CMC. Samples are incubated for 20 min at 4°C. 
After the detergent incubation period, detergent solubilized samples were centrifuged at 17,000 
RCF for 30 min and the supernatants loaded on a dot blot apparatus for quantification using a 
His-tag. Three different volumes of sample are loaded 1, 4 and 8 μL. Analysis of the dot blot 
western provided the means to identify the best extracting detergent candidates compared to the 
control, ‘‘buffer only’’ aliquot. 
2.4.3 Identifying Conditions for a Monodispersed PTHR1 Sample 
 After the best extracting agents had been identified the next step was to determine if the 
receptor was monodispersed in these detergents, and if so in what concentration. To determine 
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this dynamic light scattering (DLS) experiments were performed. Purified PTHR1 at a 
concentration 4 mg/mL was spun down at 17,000 RCF before being loaded into a 384-well 
Corning plate and analyzed in batch mode using a Wyatt DynaPro Plate Reader in the presences 
of different detergents in varying concentrations. 0.75 mM Fos-Choline 14 was found to 
facilitate the greatest monodispersity of the receptor. 
2.4.4 Purification of PTHR1 and its Truncation Fragments 
A single colony was used to inoculate TB medium containing 100 µg/ml ampicillin 
grown at 37°C until an OD600 of 1.0 was reached.  Cells were then cooled to 25°C for 30 mins 
and induced with 125 μM isopropyl-β-D-thiogalactopyranoside (IPTG). Cells were harvested 
after 16 hrs, flash frozen in liquid N2 and stored at -80°C. 
All purification steps were performed rapidly at 4°C to prevent proteolysis.  Cell pellets 
were homogenized in buffer A consisting of 150 mM NaCl, 25 mM Tris pH 8.0, and 1 X 
Protease Inhibitor Cocktail (10 μg/ml pepstatin, leupeptin, chymostatin) plus 100 μM 
phenylmethylsulfofluoride (PMSF) and 0.5 mM ethylenediaminetetraacetic acid (EDTA). Lysis 
was performed by sonication (Sonicator 3000, Misonix), power 7.5, 4 secs on 8 secs off for 6 
mins total time. Lysate was cleared by centrifuged at 5,000 RCF for 15 mins. The membrane 
fraction was isolated by centrifugation at 100,000 RCF for 30 mins.  Membrane pellets were 
extracted in 25 mM Sarcosine, 5 mM Fos-choline 14 for 2 hrs before being spun down at 
100,000 RCF for 30 mins.  
Supernatant was loaded at 0.1 mL/min onto 4 mLs of His-Select Fast Flow Resin 
(Sigma).  Detergent exchanged was performed from 25 mM Sarcosine, 5 mM Fos-choline 14 to 
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0.75 mM Fos-choline 14. Resin was washed in stepwise gradients with 15 column volumes of 
buffer A + 25, 40 and 60 mM imidazole and eluted with 90 mM imidazole in buffer A. Elutant 
was pooled and loaded onto a HiPrep 26/10 desalting column (GE healthcare). Purified PTHR1 
was incubated for 30 mins with PTH 1-34 or 15-34 monomer species was isolated from 
oligomerized PTHR1 by separation with a Supderdex 200 16/60.  
2.4.5 PTHR1 Interaction with Biotinylated-PTH 1-34 
PTHR1 in PTHR1 buffer was incubated with and without 100 uM of N-terminally 
labeled Biotinylated PTH 1-34 for 1 hr at 18°C. Samples were subsequently incubated with High 
Capacity Streptavidin agarose beads (Thermo Sci). Sample with beads were loaded into empty 
spin columns (Bio-Rad) and washed with PTHR1 buffer five times. Beads were boiled and 
analyzed by SDS-PAGE gel. 
2.4.6 GαSβγ Purification  
Sf9 cells were co-infected with a GαS construct containing a C-terminal 10x His tag preceded by 
a TEV cleavage site and a Gβ1 Gγ2 construct via baculovirus. Harvested cells were diluted with 
buffer A (250 mM KCl, 30 mM Hepes pH 7.5, 5 mM MgCl2, 2x P.I.) with 0.6 mM C12E8. Cells 
were lysed by sonication, power 3, 10 secs on, 45 secs off for 1.20 min total time. Lysate was 
further diluted 1:1 with Buffer A and was cleared with a 100,000 RCF 30 mins centrifugation. 
Supernatant was loaded onto a column packed with His-Select Fast Flow resin loaded with at a 
speed of 0.1 mLs/min in Buffer A with a C12E8 conc of 2.5 mM. A detergent gradient was 
performed to exchange into 0.5 mM Brij 58. Resin was washed in stepwise gradients with 15 
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column volumes of buffer A with 0.5 mM Brij 58 + 20, 40 and 60 mM imidazole and eluted with 
200 mM imidazole in buffer A + Brij 58. In order to isolate a stoichiometric GαSβγ complex, 
sample was loaded onto a Q-column (GE Healthcare) and a gradient 150 mM to 450 mM KCl 
was performed. Pooled GαSβγ was incubated with TEV overnight and without His-tag was 
collected from the flow through of His-Select Fast Flow resin packed column. 
2.4.7 PTH 1-34-PTHR1-GαSβγ Complex Formation  
PTH 1-34-PTHR1-GαSβγ complex was assembled first by utilizing DLS in the manner 
described in section 2.4.3. The Brij 58 GαSβγ detergent was incrementally added to PTHR1 until 
the detergent caused aggregation. The same procedure was followed for GαSβγ to determine the 
maximal concentration of Fos-Choline 14 that it could endure. Once the tolerated concentrations 
of both detergents were determined, PTHR1 with 100 uM PTH 1-34 was left together for 1 hr. 
Subsequently PTH 1-34-PTHR1 was incubated for 1 hr with nucleotide free GαSβγ. The final 
buffer consisted of 50 mM KCl, 100 mM NaCl, 75 mM Hepes 7.5, 2 mM MgCl2, and 15 mM 
imidazole. To isolate the complex, sample was loaded onto 2 mLs of His-Select Fast Flow Resin, 
washed with 5 x column volumes with buffer + 50 mM imidazole, before elution with 150 mM 
imidazole.   
 
2.4.8 Crystallization Trials 
Purified PTHR1 and truncation fragments crystallization trials were setup with or without 
100 uM PTH 1-34 (Bachem) or 15-34 (SynBiosci). Commercially available kits from Hampton 
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Research, Molecular Dimensions and Emerald Bio were utilized for initial screening trials. In 
most instances 1-2 uL drops in a variety` of ratios were employed. Crystallization trials were 
performed, in most cases, across three temperatures, 4, 16 and 25°C. Potential hits were 
optimized along at least two variables including, salt concentration, PEG type and percentage, 
and pH. Crystallization trials were also performed using NeXtal CubicPhase monoolein and 
monoolein plus 8% cholesterol per manufacturers instructions. Agarose “in gel” screening 
experiments were performed as described in (115) for full length PTHR1 and K-480s. Bicelle 
crystallization experiments were also performed as described in (116). Seeding experiments were 
performed with the HR Teflon bead, per manufacture’s instructions. Microseed Matrix Screening 
(MMS) was performed as described in (88). 
2.4.9 Brightfield and UV Tryptophan Fluorescence Microscopy  
Visual selection using an Olympus SZX16 brightfield microscope and corresponding 
2XPFC objective were performed to identify crystallization drops that showed promising 
aggregates or near crystal hits for analysis by UV tryptophan fluorescence microscopy. Later 
rounds of experiments also utilized drops with visible precipitation with individual aggregates or 
a lawn of precipitate. Candidates selected visually were then subjected to UV fluorescence 
imaging with UV exposure from 1-5 s, using a Jan Scientific Jansi UVEX microscope. Images 
were analyzed using the Jan Scientific CrystalDetect software.  
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2.4.10 CPM Thermal Denaturation Assay  
CPM thermal denaturation assays were adapted from the work of Alexandrov AI et al.  
(69). N-[4-(7diethylamino-4methyl-3 coumarinyl)phenyl]maleimide (CPM) and sample mixtures 
were protected from light at all stages to prevent photobleaching. CPM dye powder (Sigma) was 
dissolved in DMSO (Sigma) at a concentration of 4 mg/ml and aliquoted and stored at -80 °C. 
Stock solution was diluted 1:40 in DMSO immediately before use. Reactions were performed in 
sextuplicate with a total reaction volume of 20 µl. 10 µg of PTHR1 and mutants was used for 
each reaction in PTHR1 buffer with or without PTH 1-34 or PTH 15-34 with the addition of 6 µl 
of diluted CPM dye for each replicate. PTHR1-CPM reaction mixtures were prepared in 
MicroAmp Fast Optical 96-Well Reaction Plates (Applied Biosystems). Thermal melt curves 
were performed using a StepOnePlus (Applied Biosystems) using the protein melt curve program 
with a 25-95°C, 1% gradient. A custom dye calibration was performed to use CPM as a reporter. 
Melt curve data was processed in the Protein Thermal Shift Software (Applied Biosystems). 
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3.0  USE OF TRANSMISSION ELECTRON MICROSCOPY TO IDENTIFY 
NANOCRYSTALS OF CHALLENGING PROTEIN TARGETS 
This Chapter was adapted, with permission, from: 
Stevenson HP, Makhov AM, Calero M, Edwards A, Zeldin OB, Mathews II, Lin G, 
Barnes CO, Santamaria H, Ross T, Soltis M, Khosla C, Nagarajan V, Conway JF, Cohen AE and 
Calero G. Use of Transmission Electron Microscopy to Identify Nanocrystals of Challenging 
Protein Targets. Proc. Natl. Acad. Sci. U.S.A. In press 
 
3.1 INTRODUCTION 
The emergence of x-ray free electron laser (X-FEL) based serial femtosecond crystallography 
holds the promise of solving the three-dimensional structure of proteins that can only crystallize 
as nanocrystals or are highly sensitive to radiation damage (117-121).  “Nanocrystals” (NCs) 
appropriate for X-FEL experiments are considered to be 200 nm to 2 µm (122). This size is 
constrained primarily by the requirements of the NC delivery system to the X-FEL beam. In 
addition to allowing for structure resolution of NCs by X-FEL experiments, they also provide the 
advantage of requiring no crystal cryo-protection, as these experiments are performed at room 
temperature (119, 123).  Given the new opportunities that X-FELs offer to the field of 
crystallography, efficient methodologies to detect, from single crystallography drops, and 
optimize these identified conditions yielding NCs, will be essential for future developments in 
structural biology. Current methods to detect the presence of NCs include dynamic light 
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scattering (DLS), bright-field microscopy, birefringence microscopy, and intrinsic tryptophan 
ultraviolet (UV) fluoresce imaging, as well as technologies that rely upon Second Harmonic 
Generation such as Second Order Nonlinear Imaging of Chiral Crystals (SONICC) (124, 125) 
and X-ray powder diffraction. However, limitations of these imaging techniques include: 1) 
ineffective detection of crystals smaller than 5 μm (124, 126); 2) false positive conditions as a 
result of interference from precipitate backgrounds (124, 126); and 3) false negative conditions 
resulting from the lack of tryptophan residues in the case of UV fluorescence, and from the lack 
of chiral centers in the case of SONICC (127). Although DLS can accurately measure the size 
distribution of nanometer sized protein aggregates, it is unable to unambiguously distinguish 
between amorphous or crystalline (128). Finally, X-ray powder diffraction, a method that has 
been applied to evaluate samples for the presence and concentration of NCs, requires more 
material than is produced in a single crystallization screening drop; and the use of synchrotron 
radiation is usually required to produce measurable diffraction (100). In this study we use UV 
fluorescence microscopy and dynamic light scattering (DLS) to detect crystallization drops, of 
challenging proteins such as the PTHR1, containing NCs followed by TEM to accurately identify 
protein NCs and determine NC quality by evaluating the reciprocal lattice reflections in 
diffraction patterns calculated from images. 
 
 
55 
3.2 RESULTS 
Figure 18. Four step pathway to the identification of protein nanocrystals 
A) Flow chart of the protocol used to identify protein NCs from crystallization drops. B) Representative
images of granular aggregates used for TEM. C) Brightfield and UV Fluorescence of granular aggregates, 
which can comprise UV-positive, well-differentiated nano-particles (left pair) or UV-positive, diffuse 
nano-aggregates (right pair). D) Examples of nanocrystals identified by TEM (Scale bars: CD3Delta 0.5 
μm, tPTHR 0.5 μm, RNA-Pol II-TFIIB-Spt4/5 200 nm, TFIIH 200 nm, DSZS AT 0.5 μm, Spt4/5 200 nm, 
RNA-Pol II 0.2 μm, H5N1 0.2 μm). 
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In order to develop a comprehensive method for identifying NCs, a four-step pathway was 
devised (Figure 18). A variety of targets from three different systems were chosen as test cases, 
including soluble proteins, membrane proteins, and multi-protein complexes as shown in Table 
3.  
Table 3. Proteins used in nanocrystallography screening 
To the left of each SDS-PAGE gel showing the final purified protein is the full name of the protein, the 
expression system along with the protein yield and protein concentration used for setting up trays. 
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Crystallization of protein samples using commercially available screens typically yields a 
spectrum of morphologies including: 1) clear drops Figure 19A; 2) drops with granular 
aggregates (which can be amorphous or comprised of well-differentiated individual particles) 
(Figure 19B); 3) drops with large solid aggregates (probably associated with sample 
denaturation) (Figure 19C); and 4) drops with phase separation. Such morphologies depend on 
the protein sample and the chemical nature of the precipitant Figure 19. For this study, 
conditions yielding granular aggregates (Figure 19B) and clear drops were selected for further 
analysis. 
Figure 19. Representative brightfield microscopy images of typical crystallography screening 
experiment outcomes 
To determine whether granular aggregates were proteinaceous in nature, UV tryptophan 
fluorescence microscopy was used (Jansi UVEX) (129). Drops with UV-positive granular 
aggregates were selected for direct TEM visualization (Figure 18C). Since clear drops have been 
shown to yield NCs (130), and UV tryptophan fluorescence microscopy can yield false negatives 
(16) (131) UV-negative granular aggregates and clear drops were further processed using DLS to 
A) clear drops, B) granular aggregates and C) denatured protein. Scale bar (A) 300 μm (B) 300 μm and (C) 160 μm.
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assess the presence of nanoparticles (Figure 20). DLS measurements were performed using a 
Wyatt DynaPro Plate Reader Plus in batch mode (ideal for screening large numbers of 
crystallization conditions). In order to accurately assess the size of the primary nano-species of 
the sample, calibration studies using nanospheres (Polysciences, Inc.) with particle radii of 50, 
100 and 1000 nm were compared to the sample’s autocorrelation function and decay time 
(Figure 20A). DLS measurements of clear drops and UV-negative granular aggregates allowed 
detection of particles with diameters of 50-1000 nm (Figure 20B). In order to determine whether 
these particles were crystalline or merely protein aggregates, further assessment using TEM was 
performed.  
Figure 20. Comparison of correlograms of commercially available nanospheres, PTHR1 and salt 
UV- and DLS-positive samples were applied to a copper grid with continuous carbon film, 
stained with a 2% solution of uranyl acetate and imaged using an FEI Tecnai T12 transmission 
electron microscope. Samples were taken directly from the crystal tray before transferring to a 
grid. In most circumstances, a single crystal drop containing thick aggregates was of sufficient 
concentration for imaging. For the majority of samples tested, TEM visualization (Figure 21) 
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provided an efficient method to reveal whether samples contained NCs or large protein 
aggregates. In addition, the presence of detergents in crystallization buffers did not appear to 
have a negative impact on visualization, and we were able to detect NCs for three membrane 
proteins, T-cell surface glycoprotein CD3 delta chain (CD3Delta), thermostabilized Parathyroid 
Hormone Receptor (tPTHR) and Influenza Virus Hemagglutinin protein (H5N1) (Figure 18D). 
Since TEM allows visualization of crystal lattices, protein NCs could be discriminated from salt 
crystals, including those coated with protein aggregates that generated false-positive UV-signals 
(Figure 22A). 
Figure 21. TEM images of NCs (center), accompanying lattice and FFT (left) and X-FEL 
diffraction pattern (right) 
A) DSZS AT diffraction up to 1.8 Å resolution. B) RPBII -GFP with diffraction up to 4 Å acquired at
LCLS. Scale bar from top left to larger image (A) 20 nm and 1 μm, (B) 50 nm and 100 nm 
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X-FEL experiments were used to test diffraction of NCs with high quality lattices. Both, 
the trans-acting acyl transferase from the disorazole synthase DSZS AT (Figure 21A) and 
RBPII-GFP (Figure 21B) yielded significant diffraction. On the other hand, NCs of PTHR1 with 
poorly ordered lattices showed no diffraction. Lattice visualization of thick NC was performed 
by fragmentation using 0.5 mm glass beads. This was a highly successful means of expanding 
the size range of NCs examined by TEM as shown in Figure 23. 
Figure 22. Commonly observed salt nanocrystals 
   
UV- and DLS-positive samples were applied to a copper grid with continuous carbon film, 
While most NCs identified by TEM came from crystallization drops with UV-positive granular 
aggregates, a few were identified from UV-negative granular drops using DLS. We were unable 
to find protein NCs in clear drops that were preselected via DLS – most particles observed by 
TEM corresponded to large protein aggregates and salt crystals. However, since our observations 
were performed in a relatively small number of samples (around one hundred crystal drops), 
thorough DLS evaluation of all conditions may provide hits when UV positive conditions are 
scarce.  
A) Calcium chloride NCs coated in protein filaments, B) Bis-tris pH 6.5 & PEG MME 2000, C) Sodium chloride D)
Tacsimate (Hampton Research). Scale bars (A) 20 nm, (B) 50 nm, (C) 2 μm and (D) 0.5 μm. 
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Figure 23. Lattice visualization of thick RPBII-II NC after fragmentation using 0.5 mm glass 
beads 
3.3 DISCUSSION 
Crystallization screening of protein samples involves setting up hundreds and sometimes 
thousands of crystallization drops often without a single macro-crystal ‘hit’. However, the 
emergence of X-FEL based serial femtosecond crystallography demonstrates that the field of X-
ray crystallography can be expanded to solve three-dimensional structures of protein samples  
from NCs (117-121, 129, 132). To this end, an efficient method to detect the presence of protein 
NCs in UV-positive granular aggregates from crystallization drops using classic negative-stain 
transmission electron microscopy was developed.  
This investigation demonstrates that crystallization trials of most protein samples can 
potentially yield NCs even for challenging systems such as membrane proteins like the PTHR1 
as well as multi-protein complexes. In addition to NC identification, the use of TEM may 
provide additional insights including: 1) the possibility of finding NCs with different crystals 
forms; and 2) the evaluation of NC diffraction quality. Since crystalline lattices can be directly 
visualized with TEM, calculating Fourier transforms from the images allows qualitative 
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evaluation of electron diffraction patterns (Bragg spots). Three examples of clear lattices with 
two or higher order spots are evident in the reciprocal lattice reflections obtained by Fourier 
transform Figure 24. However due to the limitations of negative stain techniques using uranyl 
acetate –including room temperature diffraction, sample dehydration and possibly crystal 
cracking due to interference of the dye with the crystal lattice– restricted electron diffraction to 
low resolution (approximately 20 Å resolution). In spite of these limitations these experiments 
suggest that selection of crystals with higher order diffraction spots could potentially yield higher 
resolution X-ray diffraction data.  
Figure 24. High quality lattices of NCs visualized by TEM 
This is not the first characterization of NCs by TEM, but rather shows that NCs are 
commonly observed in crystallization drops of proteins of high biological interest; and that 
evaluation of the crystal lattices of negatively-stained NCs can provide preliminary qualitative 
information of their diffraction potential. Recent efforts have provided detailed characterization 
of lysozyme NCs electron diffraction by calculating FFT from their highly ordered lattices (107). 
Moreover, electron diffraction experiments where three lysozyme NCs were used to collect a full 
tilt-series allowed lysozyme structure determination by molecular replacement and refinement to 
2.9 Å resolution (101). Given these new advances, the work presented here offers the possibility 
A) Lysozyme B) RPBlI-GFP, C) Pol-TFIIF. Scale bar (A) 50 nm, (B) 100 nm and (C) 20 nm.
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to expand electron crystallography studies to proteins of high biological relevance. Moreover 
electron crystallography techniques could supplement X-FEL experiments for those proteins that 
cannot yield the high crystal volumes required. Electron crystallography is a field under 
development and further experiments will be required to prove its feasibility on NCs of other 
biological samples and ultimately the diffraction resolution that can be achieved using this 
technique (since lysozyme dataset was refined to a final resolution of 2.9 Å (20)), while 
conventional X-ray diffraction experiments of lysozyme crystals can reach atomic resolution. 
This chapter presents a method for pre-screening NCs with no previous large crystal hits 
for use at an X-FEL. This work demonstrates the potential of TEM to serve as a fundamental tool 
for evaluating NCs, as essential as brightfield microscopy is for evaluating and optimizing 
traditional, large crystals. 
3.4 MATERIALS AND METHODS 
3.4.1 Protein Production and Crystallography Condition Screening 
Eight proteins were used for nanocrystallography screening, as shown in Table 3 along 
with the expression system, protein yield and maximal concentration (while maintaining 
monodispersity) that was used to set up trays. The expression and purification of PTHR, CD3-
Delta and RNA Polymerase (RPBII) and complex formation with RPBII were performed as 
described (133) while DSZS AT expression and purification are described separately (134). 
Thermostabilized PTHR (tPTHR) was purified following the same protocol as described for full 
length PTHR. TFIIF was purified as previously described (135). GFP was expressed and purified 
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by standard methods (136). RPBII-TFIIF and RPBII-GFP complexes were assembled by adding 
2.5 molar excess of TFIIF or GFP to RPBII. RPBII-TFIIF was purified using calmodulin-affinity 
chromatography. The RPBII-GFP complex was isolated using a Superdex 200 10/300 GL (50 
mM Hepes pH 7.5, 100 mM KCl, 4 mM DTT, 2 mM CaCl2 and 10 μM ZnCl2). Spt4 and Spt5, as 
well as TFIIB and H5N1 were purified as described in (137). Lysozyme NCs were grown with 
protein purchased from Sigma and was crystallized in the presences of 10% NaCl and 100 mM 
sodium acetate.  
A variety of commercially available crystallography screens were utilized for 
nanocrystallography screening including the Hampton Research screens Crystal Screen 1 and 2, 
Index, PEG/Ion, SaltRx, Silver Bullets and MembFac as well as Qiagen JCSG. Both hanging 
(Hampton Research VDX™ Plates) and sitting drop (Hampton Research Cryschem Plates) 
methods were used for screening 4 µl drops, they were set up in a 1:1 ratio of protein to 
precipitant so as to have sufficient volume for further DLS and TEM experiments. 350 μl of 
commercial screening solution was used in the well for each condition. 
 
3.4.2 Generating Crushed Crystals of Thick Nanocrystals 
0.5 mm glass beads (Research Products International) were used to crush NCs too thick 
for lattice visualization by TEM.  20 mg of beads were placed in a 1.5 µl microcentrifuge with 
the addition of the NC sample directly from the crystal plate along with 5 μl of reservoir 
solution. Samples were vortexed for 10 sec, twice, before being used for TEM grid preparation. 
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3.4.3 Generating Crushed crystals of the DSZS AT for X-FEL analysis 
The DSZS AT was purified and crystallized as previously described (134), by mixing 10 
μl well solution with 10 μl of purified protein at 5 mg/ml, and allowing crystals to grow at room 
temperature for up to one week. The crystallization solution contained 18-24% PEG 3350, 100 
mM Na-HEPES pH 7.5, and 40 mM ammonium acetate. Approximately 900 μl of drops 
containing crystals were collected. When the crystals had settled to the bottom of the tube, we 
estimated that the mixture contained approximately 50% crystals. The crystals were held at room 
temperature until crushing and exposure to the LCLS X-FEL. The tube was inverted several 
times to re-suspend the crystals, and the samples were crushed in 90 μL aliquots by vortexing at 
high speed for 3 min with a Teflon seed bead (Hampton Research HR2-320). Examination of 
crystal samples under a standard light microscope revealed large crystal fragments (edges >10 
μm). Therefore, samples were further processed through a 10 μm3 filter prior to exposure with 
the LCLS using the Coherent X-ray imaging (CXI) instrument.  
3.4.4 X-FEL Analysis of Nanocrystals 
Diffraction experiments were carried out at the CXI endstation of the LCLS (138) using 
10.5 keV x-ray pulses of 40 fs duration for measurements of RPBII-GFP and PTHR  and 8.5 keV 
x-rays pulses of 50 fs duration for DSZS. Crystal delivery was performed using the gas dynamic 
virtual nozzle (GDVN) (101) using an injection rate of 20 μL/min and a pressure of 750 PSI 
nitrogen, 300 PSI shield. Data were analyzed using the CCTBX.XFEL software package (139).  
The RPBII-GFP sample yielded a hit rate of approximately 2.5%, and an indexing rate of 0.6%, 
25% of hits (using a threshold of 16 spots above 450 ADUs per image). Resolution of the best 
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images was up to 4 Å. The DSZS sample yielded a hit rate of approximately 2.7%, and an 
indexing rate of 0.07%, 29% of hits (using a threshold of 16 spots above 450 ADUs per image). 
Resolution of the best images was up to 1.8 Å. 
3.4.5 Nanocrystals Candidate Identification and UV Tryptophan Screening 
 Visual selection using an Olympus SZX16 brightfield microscope and corresponding 
2XPFC objective was performed to identify nanocrystal candidates. Drops that either had visible 
precipitation with individual aggregates or a lawn of precipitate were selected for UV-
fluorescence imaging, as shown in the examples of Figure 1B and Supplemental Figure 1. 
Candidates selected visually were then subjected to UV fluorescence imaging with UV exposure 
from 1-5 s, using a Jan Scientific Jansi UVEX microscope. Images were analyzed using the Jan 
Scientific CrystalDetect software. Once UV-positive conditions were identified, drops were 
harvested and high quality images were taken of each drop using an Infinity 2-3C camera and 
Infinity Capture software from Lumenera Scientific. Harvested drops were subsequently used for 
DLS and TEM experiments. 
3.4.6 Dynamic Light Scattering 
To test the limits of the Wyatt DynaPro plate reader for detecting nanoparticles of various 
radii, silica spheres (PolySciences, Inc) experiments were performed in a 384 Corning clear 
bottom plate using beads diluted 1:1000 with Millipore water with 15 μl of diluted beads 
deposited in the well. DLS data was acquired by performing 20 acquisitions, 6 sec each 
acquisition, at 18 °C.  
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To determine the uniformity as well as the range of the precipitate size of selected 
nanocrystal candidates, samples were taken directly from the drop of the crystallization plate and 
put into a Greiner Sensoplate (glass bottom) 1536 well plate and DLS data was collected for 20 
acquisitions, 6s each acquisition, at 18°C. These plates allowed a low working volume for 
screening (3 μl) as well as enhanced data clarity due to their glass bottoms. Samples were diluted 
with precipitant up to a volume of 3 μl when necessary. If low intensity was observed and 
sufficient protein was available, additional drops were set up using the same conditions and 
combined to increase intensity.  
3.4.7 Transmission Electron Microscopy 
400 square mesh copper grids with continuous carbon film (Electron Microscopy 
Sciences) were freshly glow-discharged for 1 min, 25 mV (EmiTech KX100) before incubation 
with samples. Selected samples were applied to grids by two methods depending on the 
concentration of nanoparticles. When a sufficiently high concentration of particles was present 
(i.e., when particles were visible, dense and gave a DLS intensity signal above 1.25), 5-8 μl of 
sample was applied and incubated for 30 sec on a grid before blotting and staining with 2% 
uranyl acetate. Lower density samples were applied to the grid by placing a drop of the sample in 
a parafilm-lined petri dish along with at least 300 µl of precipitant from the sample’s origin in 
close proximity to the sample drop. A grid was put on top of the drop of sample, carbon side 
down, and the petri dish was sealed and the sample was allowed to incubate for 10-60 min before 
staining with uranyl acetate. TEM images were acquired using an FEI Tecnai T12 electron 
microscope operating at 120 kV using a single-tilt specimen holder. Images were collected with 
a 2 k x 2 k Gatan UltraScan 1000 CCD camera.  
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4.0  TRANSMISSION ELECTRON MICROSCOPY AS A TOOL FOR NANOCRYSTAL 
CHARACTERIZATION PRE- AND POST- INJECTOR 
This Chapter was adapted, with permission, from: 
Stevenson HP, DePonte D, Zeldin OB, Boutet S, Calero G, Cohen AE. Transmission electron 
microscopy as a tool for nano-crystal characterization pre- and post-injector.  
Phil. Trans. R. Soc. B. In press 
4.1 INTRODUCTION 
As described in sections 1.2.2.1 and 3.0 the intense, ultra-short pulses produced by the 
Linac Coherent Light Source (LCLS) at SLAC have expanded the boundaries of structural 
biology research, enabling the collection of atomic resolution X-ray diffraction patterns from 
protein crystals that are too small or too radiation sensitive for conventional data collection at 
synchrotrons. In less than 50 fs, a pulse delivered by the LCLS X-FEL can expose a crystal to as 
many X-ray photons as a typical synchrotron beam produces in about a second. This has enabled 
a ‘diffraction before destruction’ (140) approach to overcoming radiation damage, where a single 
diffraction image is produced by a single LCLS pulse before a crystal succumbs to the damaging 
effects of X-ray exposure; and to obtain a complete dataset, single shot diffraction patterns from 
thousands of individual crystals are combined (122). These experiments are carried out in 
vacuum (to reduce background scatter) at the Coherent X-ray Imaging endstation (CXI) at the 
LCLS (138). Injectors are used to deliver crystals of submicrometer dimensions (or up to 5µm) 
 70 
suspended in small diameter jets or drops of aqueous solutions (101) to a series of LCLS X-ray 
pulses, produced at a repetition rate of up to 120 Hz. These innovations have enabled serial 
femtosecond crystallography (SFX) experiments to solve crystal structures using diffraction data 
from nano-meter sized crystals (117-121, 141) opening the door to obtain atomic information 
from proteins whose intrinsic disorder prevented formation of micro-meter sized crystals such as 
many membrane proteins and large multi-protein complexes (MPCs).  
The first SFX experiments used a Gas Dynamic Virtual Nozzle injector (GDVN) (101, 
142) for crystal delivery. The GDVN (117, 118, 120, 122, 143-147) is currently the primary 
injector supported at CXI for crystal screening experiments. Other sample delivery systems, such 
as the nanoflow electrospinning injector (147), have subsequently been developed and offer 
advantages such as reduced flow rate and thereby lower sample consumption by minimizing 
sample loss between X-ray pulses. Acoustic and micro-piezo activated drop-on-demand 
technologies are also in development.  
The high demand for LCLS beamtime necessitates careful sample pre-characterization 
and injector compatibility testing to ensure efficient use of this limited resource. It is standard 
practice to test the crystal containing solutions with an offline sample injector prior to beam time 
to detect problems with jet formation due to solution bubbling, clogging from crystal clumping, 
or the solution drying out as it exits the injector nozzle and enters the vacuum chamber. These 
issues may often be eliminated by modifying the carrier solution, for example by minimizing the 
use of detergents or reducing salt concentration. For crystal and solution optimization, an offline 
setup of the GDVN injectors is available to users through the sample-delivery group at the 
LCLS. These flow tests however do not detect the presence of diffraction quality crystals in the 
injector reservoir, or exiting the injector nozzle.   
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Nanometer sized crystals (NCs) of membrane proteins and large MPCs are often 
mechanically fragile. This fragility maybe further aggravated during the sample delivery process 
by exposure to high pressure and shear forces. Furthermore, injector efficiency may be reduced 
by NC clumping and aggregation in fittings such as those connecting the sample reservoir to the 
nozzle capillary. Therefore, methodologies to detect the presence and quality of NCs within the 
injector reservoir, and exiting the injector nozzle are essential to test the applicability of injector 
technologies to specific NC types, and to optimize the carrier solutions. 
The work presented here demonstrates the potential of transmission electron microscopy 
(TEM) to serve as a tool for detecting and evaluating NCs both before and after the injection 
process. NC diffraction quality may be assessed by calculating the electron diffraction pattern of 
the NC lattice by Fast Fourier Transform (FFT).   
4.2 RESULTS 
Three types of NCs were tested. The PTHR1 was selected as a representative membrane protein. 
The PTHR1 is an example of a protein where only NCs, 200-500 nm in size, have been 
produced. The second type, a construct comprising a calmodulin-green fluorescent protein (GFP) 
chimera bound to calmodulin-binding peptide (CBP) tagged Rpb4 subunit of RNA polymerase II 
(RPBII-GFP) serves as a representative MPC.  This is a green-colored protein with a large 
crystal lattice readily identifiable by transmission electron microscopy with crystal sizes ranging 
from 1-5 µm. The crystallization conditions for these systems were determined through direct 
examination of commercial crystallization screening drops using a novel selection protocol that 
combines 1) brightfield microscopy, UV fluorescence microscopy and dynamic light scattering 
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(DLS) as screening methods to detect crystallization drops containing NCs; and 2) transmission 
electron microscopy to accurately identify protein NCs and determine NC quality (133). 
Lysozyme NCs were also tested as a soluble protein control.  
Figure 25. TEM images of pre- and post- jet nanocrystals 
As shown in Figure 25A and B both lysozyme and RPBII-GFP survived the injector. 
Both pre-injector and post-injector NCs show clear identifiable lattices and at least third order 
evenly distributed Bragg spots obtained by Fast Fourier Transform (FFT) of the TEM images. 
A) Lysozyme pre- and post- jet, left to right, b) RPBII-GFP
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The lattices for lysozyme were observed to be of similar quality both pre- and post-injector.  As 
shown in Figure 25B, the quality of the post-injector RPBII-GFP NC lattices was slightly 
decreased, as indicated by a reduction of Bragg spots from the FFT. As expected from our TEM 
pre-screening results, during X-ray screening at LCLS CXI the RPBII-GFP NCs produced a 
number of quality diffraction patterns to 4 Å resolutions, as shown in Figure 26.  
Figure 26. X-ray diffraction image from RPBII-GFP collected at LCLS in Nov 2013 
For PTHR1 the overall NC concentration was reduced post-injector. A few examples of 
crystals with a more distinct lattice Figure 27 were found in the post-injector grids that were 
more sparsely populated; however the overall change in lattice quality was modest, and did not 
differ pre- and post-injector. A significant contributor to the lower post-injector NC 
concentration observed in this case is the tendency of these NCs to clump together and gather in 
the fitting located just prior to the GDVN nozzle capillary. Modification of the internal form 
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factor of the tubing-to-capillary connection may help resolve these problems. To reduce 
clumping during the experiment at CXI, crystallization conditions were optimized by adjusting 
PEG and salt concentrations. No diffraction was observed from PTHR1 during SFX experiments 
at CXI. However, a distinct low resolution powder ring (40 Å) was observed when a loop of this 
NC containing reservoir solution was tested at the Stanford Synchrotron Radiation Lightsource 
BL12-2 at RT using a 20 x 20 µm X-ray beam at 12.5 keV. While the lack of diffraction 
observed during SFX experiments may be due to a low concentration of NC in the post-injector 
solution, resulting in zero diffraction ‘hits’, we attribute this negative outcome to crystal 
disorder. The FFT obtained from the TEM images of PTHR1, even for the more ordered lattice 
Figure 27, shows only low order electron diffraction and predominantly in just one lattice 
direction. While initial results for this protein have been discouraging, we expect that successful 
SFX experiments using PTHR1 and the GDVN may be feasible through careful optimization of 
crystallization conditions with NC examination pre- and eventually post-injector using TEM. 
Figure 27. PTHR1 lattice and FFT (insert) observed in the post-injector sample 
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4.3 DISCUSSION 
X-ray free electron lasers offer the possibility to solve 3-dimensional structures of proteins that 
can only crystallize as NCs, and methods to distinguish NCs, optimize NC quality, and evaluate 
ideal sample delivery options prior to beamtime are essential components for efficient use (and 
in some cases successful experiments) of these high demand facilities. This study demonstrates 
the utility of negatively stained transmission electron microscopy as a straightforward tool for 
distinguishing NCs with edges shorter than 5 µm, and for evaluating the NC lattice both prior to 
and post injector. X-ray diffraction quality of NCs may be assessed through examination of the 
NC lattice in TEM images both visually and by calculating the FFT of the image. While more 
work is necessary, these results indicate that evenly distributed 3rd order or higher Bragg spots in 
the FFT of negative stained lattice images could be a prerequisite for obtaining measureable X-
ray diffraction patterns at X-FEL sources. Since cryo-electron microscopy does not rely on the 
use of harsh stains, (potentially damaging NCs) and can provide higher resolution images, this 
method could constitute a more accurate method to evaluate NC quality. A future study to 
correlate electron diffraction with X-FEL diffraction could assist the experimenter to select the 
best possible samples to be tested at X-FEL. 
The effects that the injection process in itself could have on diffraction quality have not 
been previously investigated using TEM. These effects could be of great consequence for fragile 
crystals with high solvent contents or for membrane proteins solubilized in detergents such as the 
PTHR1. The initial results using the GDVN show that: 1) crystal concentration pre- and post-
injector may vary significantly and 2) analysis of post-injector crystals using TEM shows that 
diffraction quality of NCs could potentially be adversely affected by the delivery process. As 
indicated by the examination of RPBII-GFP crystals that have 75-80% solvent content, these 
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effects could be of particular relevance for samples with high solvent content. The success of 
SFX experiments may be appreciably improved through careful optimization of the carrier 
solutions and injector configuration for particular nano-crystal types through the use of TEM to 
assess diffraction quality both pre- and post-injector. 
4.4 METHODS 
4.4.1 Protein Expression and Purification 
PTHR1 and RPBII were expressed and purified as described previously (133). GFP was 
expressed and purified by standard methods (136). RPBII-GFP complex was assembled by 
adding 2.5 molar excess of GFP in the presence of 1 mM CaCl2 to promote calmodulin-CBP 
binding followed by isolation using a Superdex 200 10/300 GL (50mM Hepes pH 7.5, 100 mM 
KCl, 4 mM DTT, 2 mM CaCl2 and 10 μM ZnCl2).  
4.4.2 Protein Crystallization 
Lysozyme NCs were grown with protein purchased from Sigma and were crystallized in 
the presences of 10% NaCl and 100 mM sodium acetate. Crystallography conditions for PTHR1 
NCs were 200 mM NaCl, 100 mM Bis-Tris pH 5.5, 25% Polyethylene Glycol (PEG) 3350. 
RPBII-GFP nanocrystals were grown under 4-6% PEG 8000, 200 mM MgCl2, 1 mM CaCl2, 100 
mM Tris pH 7.5 and 10 mM dithiothreitol (DTT).  
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4.4.3 GDVN Injector 
An offline GDVN injector was setup on the laboratory bench and an optical microscope 
was used to observe the nozzle and appearance of the ejected NC containing solution. The 
GDVN nozzle consists of two coaxial capillaries; a smaller diameter capillary (40 µm ID) that 
transports the crystal containing solution is centered inside a larger capillary that delivers a 
pressurized gas stream (typically helium) that surrounds and focuses the liquid stream as it exits 
the nozzle. The same nozzle was used to eject the PTHR1 and the RPBII-GFP solutions and a 
comparable nozzle was used with the lysozyme solution.  For each tested solution the gas and 
liquid pressure (on the order of 200 to 2000 psi) were varied to produce a continuous stream of 
liquid extending at least a few mm outside of the nozzle. (The X-ray interaction region is around 
100 µm from the end of the nozzle.) Table 1 lists the gas and liquid pressures used for each NC 
type. While the GDVN normally delivers solution into a vacuum chamber, for these experiments 
it was operated in air to facilitate collection of the post-injector solutions. The liquid stream from 
the GDVN is about 5 µm in diameter, travels at a velocity of about 10 m/s and may transport 
suspended crystals with edges of 10 µm or less. To prevent clogging, the crystal containing 
solutions may be first filtered, typically by a 10 µm porosity filter, before flowing through a 
1/16” outer diameter tubing reservoir connected to the central capillary of the GDVN nozzle. 
Solutions exiting the GDVN nozzle were collected onto an upper portion of an inside wall of a 
centrifuge tube which was immediately sealed. To help prevent dehydration, the bottom of the 
centrifuge tube contained a small amount of crystallization precipitant solution (protein free). 
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Crystal Type Crystallization / Carrier Solution Crystal Volume (%) 
Liquid 
Pressure (psi) 
Shield Gas 
Pressure (psi) 
Lysozyme 10% NaCl, 100 mM Na Acetate 80 500 550 
PTHR1 200 mM NaCl, 100 mM Bis-Tris 
pH 5.5, 25% PEG 3350 
30 1200 932 
RPBII-GFP 4-6% PEG 8K, 200 mM MgCl2, 1 
mM CaCl2, 100 mM Tris pH 7.5 
and 10 mM DTT 
60 750 300 
Table 4. Nanocrystal conditions used with the benchtop GDVN injector 
4.4.4 Transmission Electron Microscopy 
NC samples were harvested both pre- and post-injector, then stored on ice until needed 
for grid preparation. Copper grids with carbon film (Electron Microscopy Sciences) were made 
hydrophilic in a glow discharge for 1 minute at 25 mV (EmiTech KX100). The samples were 
incubated on a hydrophilic grid for 1 minute, blotted and twice incubated in 2% uranyl acetate 
solution for 30 seconds. The resulting crystal confluence was approximately 70% pre-injector 
and 45% post-injector for the lysozyme samples, 45% pre-injector and 10% post-injector for the 
RPBII-GFP samples and 15% pre-injector and very low post-injector for the PTHR1 samples. A 
FEI Tecani T12 electron microscope operating at 120 kV, using a single-tilt specimen holder, 
equipped with a 2 k x 2 k Gatan UltraScan 1000 CCD camera for acquiring images, was used to 
visualize sample grids. Using the FEI T12 User Interface program, images were acquired using 
auto-exposure and low dose mode. The focus of the images was adjusted by minimal contrast 
and by live FFT. The images were defocused by -500 to -1500 nm in order to obtain more 
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distinct lattice fringes. A select region of the NC lattice underwent a fast Fourier transform using 
DigitalMicrograph (Gatan, Inc).   
4.4.5  Diffraction Screening at CXI 
SFX experiments using solutions of RPBII-GFP and PTHR1 receptor were carried out at 
the LCLS CXI instrument (138) using 10 keV X-ray pulses of 40 fs duration with focus size of 
200 nm at the X-ray interaction region. The GDVN injector was used for sample delivery using 
solutions with crystal concentrations of approximately 30% NCs w/v. Diffraction patterns were 
recorded at 120 Hz using a Cornell-SLAC Pixel Array detector (148) and analyzed in real time 
using cctbx.xfel (139). Only RPBII-GFP yielded diffraction patterns, and a 2.5% hit rate was 
obtained with 25% of hits producing indexable images. Hits were determined with a threshold of 
200 ADU (determined from light averages of the data) and indexing was performed using the 
mod_hitfind module of cctbx.xfel with a target cell determined from previously acquired 
synchrotron datasets. 
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5.0  NANOSEEDING: A NEW METHOD TO GROW CRYSTALS OF SPECIFIC SIZE 
FROM A VARIETY OF SEED SOURCES 
5.1 INTRODUCTION 
X-ray crystallography remains the most successful method to obtain structural 
information from biological targets, and structures solved by this method comprise 80% of the 
current protein data base entries. Advances in molecular biology and biochemical techniques 
have allowed expression and purification of a significant number of new protein targets 
including pharmacologically relevant proteins (149-151). Similarly, innovations in synchrotron 
science including development of micro-focused x-ray beams and advances in detector 
technologies as well as development of user-friendly crystallography software packages have 
expedited crystal-to-structure time frames. However, in spite of the abundance of targets and the 
increasingly faster crystal-to-structure pipeline, crystallization of protein targets remains the 
most significant bottleneck in structure determination by X-ray crystallography. These 
challenges have persisted despite the significant advances in protein modifications to enhance the 
crystallizability of challenging targets. These novel efforts include target manipulations such as 
alanine-scanning mutagenesis (152-156), thermo-stabilization (156, 157), chimeric proteins 
favoring crystal contacts (53, 56) or stabilizing Fab (158, 159), and nano-bodies (44, 160). 
Though these techniques have led to successful three-dimensional structures of an increasing 
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number of pharmacologically relevant proteins, challenges still remain in crystallizing a variety 
of protein targets of interest. 
Seeding is another long-standing optimization tool in the crystallographer’s arsenal. This 
technique refers to three main approaches. Macroseeding is a technique that traditionally refers 
to the process of transferring small crystals or crystal fragments into a series of stabilizing wash 
solutions. After washing the small crystal it is transferred into a pre-equilibrated drop in order to 
grow the crystal larger (85, 161). Microseeding involves removing crystals from a drop, 
transferring them into a stabilizing solution and then crushing them and performing a dilution 
series of the crushed crystal seeds (86, 87).  Seed solutions are then introduced into new 
crystallization drops using a probe in the hopes of growing larger or more ordered crystals. In 
both instances the aim is to take microcrystals or fragments from large crystals and seed them 
into a metastable supersaturated protein drop to provide nucleation sites while controlling 
growth.  
Another approach to seeding is microseed matrix screening (MMS) which is becoming a 
popular technique due to its adaptability to robot crystallization tray setup (88, 89). MMS is 
performed first by setting up traditional commercially available screens and subsequently 
identifying crystals hits, likely of poor quality, to use as seeds. Low quality crystal hits are 
homogenized, pooled, and the resultant seeds are added to a new set of screening experiments, 
using the same screen from which the seeds were extracted. The challenge for this technique, 
however, is to adequately separate useful seeds from those that will have a deleterious effect on 
attempts to obtain higher quality crystals or are simply from a salt source that is indistinguishable 
from protein. Furthermore, this technique has only been proven useful with visible crystals and 
does not utilize precipitates. 
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In this work I present a method to generate nanometer-size seeds (nanoseeds) obtained 
from crystals or nanocrystals (NC) from granular aggregates; evaluate their quality by examining 
crystal lattices using TEM; and perform nanoseeding experiments to obtain large, high quality 
crystals for conventional X-ray diffraction experiments, or crystal catalogs, i.e., homogeneous 
sets of crystals of varying sizes for X-FEL and X-PP experiments.  
5.2 RESULTS 
5.2.1 Transmission Electron Microscopy of Protein Nanoseeds 
Crystals of two macromolecular complexes refractory to conventional optimization 
protocols including precipitant and protein concentration, pH, temperature and additives were 
selected for micro-seeding experiments. Characteristically, crystals were small (<150 µm for PB-
15 and <20 µm for PB-25 two unique RPBII complexes), lacked defined edges, diffracted to 8 Å 
and were highly mosaic. Brightfield microscopy analysis of crushed crystals using a 4 mm 
Teflon ball (Hampton Research) used for micro-seeding experiments revealed minimal and 
highly irregular crystal fragmentation (Figure 28A). Moreover, no lysis was observed for 
crystals in the low micrometer range  (10-20 µm).  
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Figure 28. NCs before and after crushing with beads 
In order to achieve better fragmentation we turned to lysis beads with lower diameters 
(0.5-1.0 mm) –routinely used for yeast lysis– and made of stainless steel –for easy removal with 
the use of a magnet. A single crystallization drop (2 µl volume) with over 30-50 crystals (ranging 
from 20-100 µm) was diluted 1:10 with 20 µl mother liquor and loaded into 1.5 ml Eppendorf 
tubes. Approximately 10 magnetic balls of 0.5 mm diameter were added to the crystal-mother 
liquor mixture and the tube was vortexed twice for 10 seconds; 2 µl of the resulting material 
were observed under brightfield microscopy (Figure 28B, right panel). This crystalline material 
(heretofore referred as nanoseeds) was homogeneous lysed and consisted of a large number of 
sub-micrometer particles with no identifiable faces or edges.  
A) Post crushing by the Teflon bead resulted in significantly less shearing than those crushed by B) the
0.5 mm beads. 
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Figure 29. TEM images of RPBII-GFP nanocrystals crushed with 0.5 mm beads 
Lastly, in order to verify that nanoseeds were not damaged during lysis, we set out to identify the 
presence of ordered lattices using transmission electron microscopy (TEM). Approximately 3-4 
µl of nanoseed material were loaded onto carbon film copper grids (Electron Microscopy 
Sciences), blotted, negatively stained with 2% uranyl acetate (30 sec incubations) and air dried. 
A) Example of small nanoseed on top of a background of polymerase particles. B) Individual sheered
lattices of RPBII -GFP. C) Nanoseed with clearly visible fracture lines (bottom right). D) Individual 
polymerase particles (left), protein filaments (middle) feeding into a small nanoseed (right). 
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Sample grids were visualized using a T12 Tecnai electron microscope. Fragmented NCs were 
easily identified under TEM. Size and thickness of nanoseeds range from 70-2000 nm and from 
one to several layers respectively (Figure 29). By using slightly larger 1.0 mm beads, we were 
able to control the size of the seeds generated (Figure 30).  
Figure 30. Evaluation of nanoseeds thickness by TEM 
Since crystalline lattices were clearly visualized with TEM, calculating Fourier transforms from 
the images allowed quantitative evaluation of electron diffraction patterns (Bragg spots) by 
selecting areas of the lattice. High quality lattices with two or higher order spots are evident in 
the reciprocal lattice reflections obtained by Fourier transform (Figure 29, insets). These results 
illustrate the potential use of TEM analysis of nanoseeds as a screening method to determine 
crystal quality. 
A) Nanoseeds with single planes of lattice generated by 0.5 mm beads. B) A nanoseed several
layers thick generated by 1 mm beads. 
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Figure 31. Comparison seeding optimization experiment set up with seeds produced by 
A) the Teflon bead verses B) 0.5 mm beads.
In addition to studying the shearing capacity of the Teflon beads vs. the 0.5 mm beads by 
brightfield and TEM, streak microseeding experiments were performed to compare the 
effectiveness of both types of seeds in generating crystals. Seeds were generated from the same 
source, which were relatively low quality crystals. As shown in Figure 31, significantly higher 
quality and larger size crystals were obtained from the 0.5 mm beads compared to the Teflon 
bead.  
5.2.2 Nanoseeding Experiments Utilizing Visible Crystals 
Once the high quality nature of the nanoseeds was confirmed, we set out to perform 
micro-seeding experiments using a nanoseed stock generated as described above. As shown in 
Figure 32A, small visible crystals were used to generate nanoseeds for this experiment. For 
nanoseeding experiments, conventional serial dilutions of the nanoseed stock (1:5, 1:25 and 
1:125) were performed in order to fine-tune crystal size and quality. Nanoseeds were deposited 
on crystallization drops using a 0.3-0.4 millimeter cryo-loops (Hampton Research). 
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“Nanoseeded” crystal drops generated high quality crystals (Figure 32). X-ray diffraction 
experiments showed overall improvement of resolution and crystal mosaicity (Figure 32, right 
panels) as expected.  
Figure 32. Brightfield images of pre and post seeding crystals, as well as post seeding diffraction 
Since all samples in our study yielded large crystals by nanoseeding methods, TEM evaluation of 
seeds may not be necessary in all cases. As an alternative, in order to evaluate NC lysis 
efficiency, homogeneity and concentration, 2 µl of sample can be sealed between cover-slides 
A) pb 15 visible crystals were used to generate nanoseeds. pb15 nanoseeded optimized crystals with
diffraction of 3.6 Å. B) RPBII -CD3Delta nanocrystals optimized into visible crystals by nanoseeding. 
Diffraction up to 4.8Å 
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for bright- and UV-microscopy inspection. Examples of nanoseeds imaged using a Jansi UVEX 
microscope with a 40X objective are shown in Figure 33. 
Figure 33. Nanoseeds, which required a 40X objective to detect by UV Tryptophan fluorescence 
5.2.3 Nanoseeding Experiments Utilizing Nanocrystals 
To detect the presence of NC in crystallization drops we followed the protocol described 
(137). Ultraviolet (UV) positive granular aggregates were selected for TEM imaging to confirm 
the presence of NCs. Crystallization conditions bearing NCs were subject to one round of 
optimization to improve NC size and/or quality and to generate larger amount of NCs for 
nanoseeding experiments. After the initial round of optimization, individual crystallization drops 
(1-2 µl) containing NCs were diluted 4X with mother liquor to a final volume of 10 µl and 
loaded into 200 µl PCR tubes containing 8-10 magnetic steel balls (0.5 mm diameter). Samples 
were vortexed twice for 10 sec. To allow use of all seeding material, magnetic balls were by 
removed by holding a magnet against the side of the tube. To corroborate proper fragmentation 
A) Brightfield and B) UV fluorescence image.
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and size homogeneity, samples were evaluated with brightfield and UV microscopy before and 
after being lysed (Figure 34).  
Figure 34. 40X objective images of brightfield UV tryptophan fluorescence of pb25 
nanocrystals before A) and after B) 0.5 mm bead nanoseeds generation 
Due to the presence of aggregates in the sample, observation of a UV signal was of paramount 
importance to allow qualitative estimate of nanoseed concentration. Seeding experiments were 
performed using nanoseeds slurries, and no serial dilutions were made for these samples since 
concentration of nanoseeds is typically low. Nanoseeded crystal drops generated high quality 
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crystals from granular precipitates (Figure 32B). X-ray diffraction experiments showed overall 
improvement of resolution and crystal mosaicity (Figure 32B right panel).  
In addition to nanoseeding being a useful initial step for obtaining higher quality crystals 
or simply optimizing NC into visible crystals, this technique is useful for a sequential seeding 
optimization approach. As shown in Figure 35 nanoseeding was an excellent technique for 
generating large diffractable crystals of this candidate from crystals that were previously to small 
and low quality for x-ray diffraction.  
Figure 35. Optimization of PolF by nanoseeding optimization experiments. 
A) Starting material used for crushing by 0.5 mm beads. B) Initial round of optimization using the seeds
generated using the 0.5 mm beads. C) Large visible crystals generated by B as starting material. 
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This optimization almost exclusively relied on multiple rounds of nanoseeding to obtain 
significantly higher quality crystals that could be used for diffraction experiments (Figure 36). 
Nanoseeding may provide a reliable shortcut for arduous optimization steps for many protein 
crystallographic targets or at the very least significantly enhance traditional optimization 
approaches.  
Figure 36. Diffraction up to 3.6 Å of pb25 after optimization by nanoseeding. 
5.2.4 Generation of Crystal Catalogues for X-FEL Experiments 
Given the advances provided by X-ray diffraction experiments using free electron lasers, 
it is very desirable to generate high quality and homogeneous population of NCs (heretofore 
referred as crystal catalogues) to be used for experiments at the Coherent X-ray Imaging (CXI) 
or X-ray Pump Probe (XPP) (>20 micrometers) facilities available at LCLS. Initially, we wished 
to explore the effects of using specifically quantified seed dilutions on crystal growth, seeded 
into varying precipitant to sample dilutions. Seeds were quantified by injecting the seed sample 
into the counting chamber of a hemocytometer and taking 40X UV images. Seeds were manually 
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counted in imageJ. As shown in Figure 37, there was a distinct correlation between both the 
precipitant to sample dilution and the quantity of seeds used dilution. 
Figure 37. Effect of varying the precipitant to sample ratio with a decrease in seed concentration 
With this in mind a protocol to generate crystal catalogues consisting of finely tuned 
crystal sizes was developed using nanoseeds. One to two drops with large numbers of crystals 
with sizes varying from 10-30 µm are diluted 30X with mother liquor and loaded into a 1.5 ml 
Eppendorf tube. Approximately 10 magnetic balls of 1.0 mm diameter are loaded into the tube 
and vortexed twice for 10 seconds followed by brightfield and UV inspection to corroborate lysis 
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efficiency and size of nanoseeds. A 1:3 dilution with mother liquor was performed with the 
seeding stock. Crystal drops were set with different ratios of volumes of protein to precipitant 
and seeded with equal amounts of nanoseeds from the seeding stock using a 0.3-0.4 millimeter 
cryo-loops (Hampton Research). As expected, all seeded drops generated collections of 
homogeneous crystal sizes (Figure 7A), while patterns were absent for non-seeded drops.  
Figure 38. Crystal catalog showing crystals of homogenously size. 
5.3 DISCUSSION 
Crystal seeding has been traditionally part art, part science. Here we present the first study using 
transmission electron microscopy of crystal seeds to develop a consistent methodology to 
generate nanoseeds from nanocrystal slurries. The high quality of these nanoseeds was 
corroborated using negative-stain TEM. Here we show that different sizes of seed lysis beads can 
be used to produce different sized seeds that have significant consequences on the growth of 
crystals by streak micro-seeding experiments. Nanoseeds were visualized directly by TEM. In all 
instances examined, nanoseeds produced by 0.5 mm beads were of high quality, as indicated by 
Refinement of crystal size was performed by varying the precipitant to protein ratio. In all cases the same 
amount nanoseed slurry was added to the crystallization drop. 
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the evaluation of the FFT of the lattice.  Use of nanoseeds were novel in four applications: 1) to 
produce improvements in crystal quality that could not be obtained through crystal condition 
optimization or traditional seeding. This was corroborated by x-ray diffraction data.  2) 
Nanoseeding of nanocrystals, not visible by brightfield microscopy and only identifiable by 
TEM, could be used in seeding experiments to produce visible crystals useful for traditional x-
ray crystallography. 3) To produce higher quality nanocrystals, as in traditional seeding results, 
improvements of which were observed by TEM. 4) Nanoseed slurries of large crystals could be 
used to produce homogenous sized crystals of differing sizes. These results have important and 
useful applications for traditional and nanocrystallography, but also serves as a probe into the 
mechanism of seeding, a technique which, though powerful, is not fully understood.  
The techniques presented here offer an essential understanding of the working of seeding 
as well as a means to obtain high quality crystals. However, it also provides a means to dictate 
the size of crystals. As the uses of nanocrystals with X-FEL to determine protein structure 
becomes more common, the ability to solve structures of crystals with a low threshold of 
radiation sensitivity becomes a significant benefit of this technique. This often means that large 
crystals must be “optimized down” to obtain high quality nanocrystals comparable with the 
current setups as CXI or XPP. This can be a tedious and unpredictable process, much like 
optimizing small crystals into larger ones. By applying the nanoseeding method, crystal size can 
be fine-tuned using a standardized amount of nanoseeds, seeded into varying ratios of protein to 
precipitant. Our results show that these experiments, when combined with nanoseed slurries, 
produce drops with homogenously sized crystals, which vary in size with the protein to 
precipitant ratio used. 
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5.4 METHODS 
5.4.1 Protein Purification and Crystallography Condition Screening 
RNA Polymerase (RPBII) and complex formation with RPBII was performed as 
described in (133) as was CD3Delta. TFIIF was purified as described in (135). Expression and 
purification of GFP was performed by standard methods (136). 2.5 M GFP or TFIIF was 
incubated with RPBII to assemble RPBII-GFP or RPBII-TFIIF. A Superdex 200 10/300 GL 
(50mM Hepes pH 7.5, 100mM KCl, 4mM DTT, 2mM CaCl2 and 10μM ZnCl2) was used to 
isolate the RPBII-GFP complex. Calmodulin-affinity chromatography was used to isolate RPBII-
TFIIF.  
Purification of CD3Delta and RPB 4-7 tagged with CBP were purified from E. coli as 
described in (133). CD3delta-CBP was stored in Buffer A (50 mM Tris-HCl pH 7.5, 600 mM 
NaCl, 0.5 mM C12E8), while RPB 4-7-CBP was stored in Buffer B (50 mM Tris-HCl pH 7.5, 
150 mM KCl, 2 mM BME, 0.1 mM C12E8, and 2.5 mM CaCl2) 
In preparation of complex formation, both CD3delta and RBP 4-7 were incubated for 15 
mins with after the addition of 2.5 mM CaCl2. All steps were performed at 4C. RBP 4-7 was 
then diluted 10X with buffer B before being combined with CD3delta and was incubated for 15 
mins. The complex was then isolated on a Q-HP GE column in which the column was washed 
with 5 column volumes of Buffer A + 200 mM KCl.  The complex was eluted in Buffer C (30 
mM Tris-HCl pH 7.5, 600 mM KCl, 2 mM BME, 0.1 mM C12E8, and 2.5 mM CaCl2). 
2.5 mM CaCl2 was added to Delta 4-7 Buffer D (30 mM Tris-HCl pH 7.5, 100 mM 
NaCl, 0.2X TEZ, 5 mM DTT, 0.1 mM C12E8, and 2.5 mM CaCl2) and incubated for 15 mins 
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before being mixed in an 1:0.6 ratio of Delta 4-7 to CD3delta-RBP 4-7 for 15 mins. This new 
complex was captured in the same way as the first and was dialyzed overnight in Buffer D. 
To assemble an elongation complex (EC) for the purification of wild-type RPBII-
nucleotide DNA/RNA scaffold-TFIIB complex (PB-25), 54-nts oligonucleotides containing a 
single stretch of 25 non-complimentary bases and a 5-mer RNA (complimentary to the template 
strand) were annealed above their melting temperatures and allowed to cool down slowly to 4 °C 
over a period of 5 hours. The resulting EC was incubated with S. cerevisiae 12-subunit RPBII 
(3:1 molar ratio) and excess EC was removed using size exclusion chromatography. TF2B was 
mixed with a RPBII-EC complex (3:1 molar ratio) in high salt buffer, removal of excess TF2B 
was carried out using a second size exclusion step in low salt buffer (50-100 mM).  
Crystallization conditions for these proteins are as follows: RPBII-GFP: 6% PEG 8000, 
0.1mM MgCl2, 100mM Tris pH 8.0, 10mM DTT, 2mM CaCl2. TFIIF: 8-12% PEG 400, 100mM 
NaMalonate, 50 mM HEPES pH 7.0 and 10 mM DTT. RPBII-CD3Delta: 1.4 M NaMalonate, 
10mM DTT, pH 6.0. PB25: 30-35% Tact mate, 100mM Hepes pH 7.0, 15mM DTT. 
5.4.2 Brightfield and UV Tryptophan Screening 
An Olympus SZX16 brightfield microscope fitted with a 2XPFC objective was used to 
screen crystallization drops for granular aggregates and visible crystals to be used for 
nanoseeding experiments. Granular aggregates and visible crystals that maybe used for 
nanoseeding experiments were screened with a Jansi UVEX microscope to determine if the 
sample was proteinaceous in nature. Image analysis was performed using the Jan Scientific 
CrystalDetect software.  
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5.4.3 Seed Bead Experiments 
HR Teflon bead fragmentation was performed according to the manufacture’s protocol. 
1.0 and 0.5 mm bead fragmentation was performed using 10 beads of stainless steel (Jinan 
Hawaii Industry Manufacturing And Trading Co. Limited) in a 1.5 mL microcentrifuge tube. 
Sample from 1-5 crystallization drops were combined and diluted with precipitant solution 
sufficient to cover just about the glass beads. Beads and sample were vortexed on high two times 
and stored on ice until grid preparation 
5.4.4 Seed Counting 
To determine seed concentration, seeds were injected into the counting chamber of a 
glass hemocytometer covered by a thin, UB transparent cover slip (HR). UV tryptophan 
fluorescent images were acquired for 1-4 sec. Images were counted using the Cell Counter 
ImageJ plugin after the image threshold was adjusted. 
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6.0  DISCUSSION 
This work seeks to determine whether elusive targets, such as the PTHR1, produce 
identifiable protein NCs in conventional crystallization trials. Chapter 2.0 demonstrates the 
challenges associated with crystallizing the PTHR1. However, as Chapter 3.0 clearly shows, NCs 
of elusive targets such as the PTHR1, along with seven other samples tested can be identified by 
TEM. Furthermore, by calculating the fast Fourier transform of the lattice, crystal quality can be 
evaluated. Chapter 4 takes the first look at what is occurring to NCs before they are delivered to 
the X-FEL beam. This chapter illustrates the need to optimize protein conditions in order to 
reduce fragility and provides a means for further optimization of the jet itself. In Chapter 5.0  I 
show that not only do fragmented seeds hold a great deal of crystal optimization potential, they 
can also serve as the link between NCs and large crystals. Together, the work presented in these 
chapters demonstrates that TEM visualization of representative NCs from all protein types can 
be identified, optimized, and used to produce structures of proteins of which no large crystal 
could be obtained previously. 
I hypothesized that protein NCs can be identified in a variety of protein targets intended 
for crystallization experiments, including samples of soluble, membrane, and multiprotein 
complexes. To demonstrate the usefulness of this strategy, the difficult Family B GPCR target, 
the PTHR1, was purified and used in crystallization trials to generate potential NCs. These trials 
revealed that alternative strategies to those employed for the Family A GPCRs would be 
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necessary to obtain large crystals of the PTHR1. The experiments presented in Chapter 3.0  
sought to determine a means to identify NCs, assess their prevalence within a sample, and 
evaluate NC quality. This study relied upon samples from a variety of challenging targets as test 
cases, including the PTHR1.  Chapter 4.0  sought to look at the next step, in which NCs are 
actually utilized in nanocrystallography diffraction experiments. Specifically, I wished to study 
the effects of the gas dynamic virtual nozzle (GDVN) on NC morphology before they reached 
the laser beam, after they are ejected from the injector. To this end, the visualization power of 
TEM was employed to examine NCs pre- and post- jet. This was performed using three different 
protein types to determine if any of the morphological changes that occurred when NCs go 
through the injector were protein type dependent. Furthermore in Chapter 5.0 , the fragmentation 
protocol used in the original Chapter 3 study to identify protein lattices of thick NCs (as well as 
judge their quality) led to the discovery that these “nanoseeds” were much more effective in 
yielding large crystals than were traditional seeding methods. Experiments comparing the 
effectiveness of traditional seeding and nanoseeding were performed. These experiments showed 
that crystals from nanoseeds were visibly larger and produced higher resolution structures. This 
study also showed that nanocrystals themselves could be used as a source to produce nanoseeds 
and could actually generate visible crystals where only nanocrystals could be grown before. 
Additionally, trials were performed to determine if nanoseeds could be utilized to create finely 
tuned, homogenous crystals useful for nanocrystallography experiments. These experiments 
clearly demonstrate the utility of nanoseeds in modulating crystal size, providing a means to use 
both the GDVN and fixed goniometer setup at LCLS’ X-ray Pump Probe facility that uses larger 
crystals. 
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In Chapter 2.0 conventional crystallization approaches were applied to crystallization 
trials of the PTHR1. However, despite applying crystallography techniques specific to GPCR, 
crystallization, trials did not yield large crystals. Included in these trials were protein 
modifications aimed at stabilizing the receptor, based on successful strategies used for 
crystallizing other GPCRs. Though no large crystals were obtained, these trials did produce 
protein NCs, as Chapter 3.0 reveals. Though these crystals are not yet of sufficient quality or 
concentration for X-FEL diffraction experiments, as illustrated in Chapter 4.0  they represent an 
exciting step forward for large protein crystallography. The obtained PTHR1 NCs represent the 
first full-length GPCR crystals described to date besides Rhodopsin/Opsin, which had small 
extracellular domains (49, 50). This development has exciting implications for the advantages of 
nanocrystallography over conventional crystallography. It suggests that in addition to being able 
to solve structures of challenging targets that were otherwise not of useful size, it is possible that 
more daring crystallization constructs could be used to obtain NCs (which otherwise could not 
grow large crystals) and subsequently use them to solve more complete structures by X-FEL. 
To successfully obtain crystals of the PTHR1, however, strategies need to focus on 
PTHR1 optimization that precedes the crystallization effort altogether. The PTHR1 was 
expressed in bacteria. This is an uncommon means to protein production for GPCR 
crystallography (162). One concern that has been reported is that GPCRs expressed in E. coli 
may sometimes produce several different populations of the receptor. These range from low to 
high affinity ligand binding receptors (163-166). As a result it may be advantageous to more 
thoroughly screen potential expression systems and weigh protein expression against the 
functionality of the receptor. One possible approach is to perform a radioligand competition-
binding assay to determine the Kd of PTHR1 expressed from various expression systems. 
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Furthermore, comparative melting temperature estimates could also be determined. To carry out 
the latter, radioligand binding assays could be performed after heating receptors produced from 
different expression systems. The amount of receptor still able to bind ligand can then be 
compared, following a similar protocol to that described in (64). This may be a useful approach 
to identify the best expression system for obtaining folded, functional PTHR1. 
However, since NCs of the PTHR1 have already been obtained for the receptor, it may be 
of greatest utility to begin optimization with the NCs themselves. The trials in Chapter 4.0  
suggest several necessary areas of improvement for PTHR1 NCs: 1) increase the abundance of 
NCs to obtain large volumes of NC slurry that are necessary to collect data; 2) follow the 
improvement of the NCs by optimizing conditions to overcome the low quality nature of the NC 
lattice; 3) reduce clogging, most likely caused by high surfactant levels in the NC slurry buffer; 
and 4) optimize NCs to reduce their fragility. 
In the instance when only low concentration of crystals can be obtained, results shown in 
Figure 38 and Figure 37 demonstrate the power of utilizing nanocrystals as nanoseeds to obtain 
a higher concentration of crystals, and in many cases obtain visible crystals. This technique in 
combination with traditional crystallography optimization approaches may ultimately provide a 
means to increase NC concentration. These figures also show the utility of seed dilutions with 
protein to precipitant modifications, and may prove to be experiments that are useful for 
increasing concentrations of NCs. Additionally, the standard crystallographic approaches, which 
include increase protein concentration, precipitating agent and salt, will likely also be useful. The 
results of these trials may be followed by TEM to determine the value of these changes, if not 
visible by brightfield microscopy. This approach may also be practical for overcoming the poor 
quality of the PTHR1 lattices shown in Chapters 3.0 and 4.0 Furthermore, given the “disordered” 
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nature of the PTHR1 lattices focusing further on thermostabilizing and truncating the receptor 
may be a practical next step.  
In Chapter 4.0  PTHR1 NCs were shown to be not yet useful for X-FEL diffraction 
experiments. In addition to the low concentration of the receptor’s NCs, these crystals, and 
RPBII-GPF NCs to a lesser extent, demonstrated fragility of NCs in the face of the harsh 
conditions of the jet. Though jet optimization may prove to be the defining factor in NC survival, 
there are several possible approaches to overcome the above-mentioned challenges. In the case 
of the PTHR1 pure protein, further detergent minded DLS experiments could be performed to 
determine the absolute lowest detergent concentration that is necessary to keep the receptor 
monodispersed. Furthermore, it may be useful to screen surfactants themselves with the jet to 
determine the best candidates for use with membrane protein NCs to prevent clogging and 
destructive bubbling.  
The fragility of NCs also decreases their probability of survival while going through the 
jet, and subsequently, the quality of the resolution that can be obtained. This inherent fragility of 
the crystals could be optimized in several ways. One of the most commonly applied methods to 
overcome crystal fragility is cross-linking. A cross-linking agent, such as 0.1% glutaraldehyde 
can be added directly to the drop or reservoir.  Cross-linking has also been shown to be useful for 
preventing lattice disorder, such as the lattice disorder observed in PTHR1 NCs (167-169). 
Dehydration is another post-crystallization treatment that is thought to circumvent the problems 
associated with crystals with large solvent content and loosely packed molecules (169, 170). This 
technique may also be a potential approach to overcome the low threshold of fragility required 
by current nanocrystallography approaches.  
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 The investigation into the damage caused by the jet to NCs was assessed for the first time 
in Chapter 4.0 . However, despite the novelty of this study it must be extended further to obtain 
more conclusive results of how the jet impacts different crystal types. Furthermore, only NC 
samples that can be obtained at the same concentration (and can subsequently be diluted in the 
same manner) should be compared in future work. This method will help to distinguish between 
damage, loss in concentration, and clogging that result from the interaction of the GDVN, on one 
hand, and the properties of the crystals and buffers themselves on the other. 
The approach followed in Chapter 4.0 could also be used as a powerful method to 
optimize the technique of GDVN itself.  Representative proteins could be tested in the same way 
as described above to evaluate the pre- and post- TEM images of NCs. This may be important, as 
loss of concentration can already be estimated, but the damage done to crystal cannot presently 
be evaluated, without the application of the TEM visualization method presented here, which 
limits the optimization of the jet delivery system. TEM may even reveal an association of NC 
disruption depending on the morphology of the crystal along with its protein type.  
 In Chapter 3.0  I sought to develop a method for rapidly identifying protein nanocrystals 
as well as a means to characterize and evaluate the identified NCs. This method is meant to be 
broadly applicable to many laboratory environments. However, in some instances, use of this 
technique maybe limited by the equipment available to a particular lab. For example, without UV 
tryptophan fluorescence microscopy in conjunction with brightfield microscopy it would be 
extremely difficult to distinguish between protein and salt precipitate. There are, however, other 
possible routes to pare down the number of samples used for TEM analysis. One laborious 
option would be to setup, in parallel, two drops for each condition and label one drop with Izit 
dye to distinguish between protein which would turn blue or non-labeled salt. As described in 
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Chapter 3.0  DLS can also be utilized as a pre-screening method to determine if precipitates 
contain species with appropriate NC diameter. However, another application of DLS could be 
utilized when equipment resources are scarce but a DLS instrument is readily available. Dierks et 
al. (171) adapted DLS to monitor protein nucleation and growth, and, in the process to 
distinguish between amorphous and crystalline species. This method could be useful when other 
pre-screening TEM approaches are not possible. However, this experiment follows newly setup 
crystallography drops over time in order to distinguish between aggregates and crystalline 
species. As such, this method may not be ideal for screening an exhaustive number of trays and 
may likely only be used for screening long after the crystallographer has given up hope of 
obtaining large crystal hits from these experiments. 
Another means of increasing the high-throughput nature of the method presented in 
Chapter 3.0 is to focus on TEM itself. The FEI Tecnai T12 microscope that was used in these 
studies has a single tilt, side loader sample setup. Changing between samples can take up to 7 
minutes, including microscope adjustment time. This can significantly inhibit the number of 
samples that can be screened per protein. There are advances in sample holder technology, 
however, that may increase the speed at which samples can be assessed. One example, which is 
still uncommon amongst non-cryo- TEM microscopes, includes multi-sample holders that reduce 
sample-changing time. Automated sample screening and image acquisition when paired with 
image recognition geared at lattice recognition may be also employed in the future. These 
improvements will allow crystallographers to screen samples rapidly to identify more quickly 
those hits worthy of further optimization. 
 The NC fragmentation protocol developed in Chapter 5.0 has implications beyond the 
advances it provides as an excellent source of seeds. In Figure 30 there is a comparison of the 
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resultant seeds by 0.5 and 1 mm lysis beads. The size of the 1 mm bead generated seeds is an 
ideal size for solving structure of 3D NCs by cryo-EM. Only one such structure has been 
reported, that of lysozyme to 2.9Å (107). One of the challenges that the authors faced was 
isolating crystals of the necessary size, which they found to be no thicker than 0.5 μm. And 
indeed, it is expected that this will be a challenge in future structure resolution by this same 
method with other protein NCs. The nanoseed protocol presented in Chapter 5.0 then, may 
provide an exciting route to increase the number of such structures by crushing crystals to the 
appropriate size for electron diffraction.  
X-FEL nanocrystallography provides a new avenue to solve crystal structures by X-ray 
diffraction of nano-meter sized crystals. These innovations open the door to obtaining atomic 
information from samples whose intrinsic disorder prevents the formation of large crystals. 
However, approaches to identify protein NCs suitable for diffraction by a X-FEL were not 
available prior to this work. Moreover, X-FEL structures solved to date were comprised mainly 
of NCs that had been previously solved by conventional X-ray crystallography methods. As a 
result, X-FEL experiments had yet to be employed to solve structures of challenging targets that 
only yield NCs. By examining crystallization drops with negative stain transmission electron 
microscopy (TEM), I have shown that NCs can be identified from all samples tested, which 
include representative proteins from a diverse population of challenging targets. In addition to 
this discovery, the application of TEM to NC visualization led to other novel findings. This 
method provided the first means to study the damage inflicted on NCs by the X-FEL NC 
delivery system, the GDVN. These studies showed that the GDVN produced different degrees of 
damage depending on the protein NC type. An additional investigation using TEM allowed for 
the first visualization of crystallographic seeds. These seed studies demonstrate that fragmented 
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NCs are powerful tools for optimizing and growing crystals. Taken together, the sum of this 
work provides a way not only to solve structures from challenging targets where large crystals 
could not be obtained, but also test whether these NCs could even survive X-FEL diffraction 
experiments prior to testing during expensive LCLS time. Furthermore this work provides a 
means to turn the NCs identified in Chapter 3.0  into nanoseeds, which can be used to grow large 
crystals from NCs. 
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ABBREVIATIONS 
GPCR G-Protein Coupled Receptor 
HGP Heterotrimeric G protein 
ECD Extracellular domain 
ILC Intracellular loop 
βAR β adrenergic receptor 
PTHR1 Parathyroid hormone receptor type 1 
NC Nanocrystal 
CRHR1 Corticotropin releasing factor receptor type 1 
GCGR Glucagon receptor 
PTHR-480s C-term PTHR truncation at residue 480s 
K-PTHR Replaced flexible ECD loop with Ser-Gly linker 
PTHR-ICL3 Replaced ICL3 of PTHR1 with Ser-Gly linker 
RPBII RNA polymerase II 
CPM N-[4-(7diethylamino-4methyl-3 coumarinyl)phenyl]maleimide 
TEM Transmission electron microscopy 
FFT Fast Fourier transform 
DLS Dynamic light scattering 
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